Login
Evidence Feed
About
Conferences
New
Diagnostics
New
Top genes
New
Contact us
^
Login
Home
>
Evidence Feed
Reset Filters
VERI cancer hierarchy
x
x
x
x
EGFR exon 19 deletion
Non Small Cell Lung Cancer
EGFR exon 19 deletion
Non Small Cell Lung Cancer
osimertinib
Sensitive: A1 - Approval
J Clin Oncol - 2 days (New B)
osimertinib
Sensitive
:
A1
J Clin Oncol - 2d
osimertinib
Sensitive: A1 - Approval
J Clin Oncol - 2 days
osimertinib
Sensitive
:
A1
J Clin Oncol - 2 days - (New B)
EGFR L858R
Non Small Cell Lung Cancer
EGFR L858R
Non Small Cell Lung Cancer
osimertinib
Sensitive: A1 - Approval
J Clin Oncol - 2 days (New B)
osimertinib
Sensitive
:
A1
J Clin Oncol - 2d
osimertinib
Sensitive: A1 - Approval
J Clin Oncol - 2 days
osimertinib
Sensitive
:
A1
J Clin Oncol - 2 days - (New B)
EML4-ALK fusion
Neuroendocrine Tumor
EML4-ALK fusion
Neuroendocrine Tumor
alectinib
Sensitive: C4 – Case Studies
Ann Transl Med - 2 days (New C4)
alectinib
Sensitive
:
C4
Ann Transl Med - 2d
alectinib
Sensitive: C4 – Case Studies
Ann Transl Med - 2 days
alectinib
Sensitive
:
C4
Ann Transl Med - 2 days - (New C4)
HR positive
HER2 Negative Breast Cancer
HR positive
HER2 Negative Breast Cancer
palbociclib
Sensitive: A1 - Approval
BMC Cancer - 3 days (New C3)
palbociclib
Sensitive
:
A1
BMC Cancer - 3d
palbociclib
Sensitive: A1 - Approval
BMC Cancer - 3 days
palbociclib
Sensitive
:
A1
BMC Cancer - 3 days - (New C3)
BRCA2 mutation
Ovarian Cancer
BRCA2 mutation
Ovarian Cancer
BSI 201
Sensitive: C3 – Early Trials
Oncologist - 3 days (New C3)
BSI 201
Sensitive
:
C3
Oncologist - 3d
BSI 201
Sensitive: C3 – Early Trials
Oncologist - 3 days
BSI 201
Sensitive
:
C3
Oncologist - 3 days - (New C3)
BRCA1 mutation
Ovarian Cancer
BRCA1 mutation
Ovarian Cancer
BSI 201
Sensitive: C3 – Early Trials
Oncologist - 3 days (New C3)
BSI 201
Sensitive
:
C3
Oncologist - 3d
BSI 201
Sensitive: C3 – Early Trials
Oncologist - 3 days
BSI 201
Sensitive
:
C3
Oncologist - 3 days - (New C3)
ROS1 positive
Non Small Cell Lung Cancer
ROS1 positive
Non Small Cell Lung Cancer
TPX-0005
Sensitive: B - Late Trials
IASLC-TTLC 2023 - 5 days (New C3)
TPX-0005
Sensitive
:
B
IASLC-TTLC 2023 - 5d
TPX-0005
Sensitive: B - Late Trials
IASLC-TTLC 2023 - 5 days
TPX-0005
Sensitive
:
B
IASLC-TTLC 2023 - 5 days - (New C3)
HER-2 mutation
Non Small Cell Lung Cancer
HER-2 mutation
Non Small Cell Lung Cancer
BI 1810631
Sensitive: C2 – Inclusion Criteria
IASLC-TTLC 2023 - 5 days (New C3)
BI 1810631
Sensitive
:
C2
IASLC-TTLC 2023 - 5d
BI 1810631
Sensitive: C2 – Inclusion Criteria
IASLC-TTLC 2023 - 5 days
BI 1810631
Sensitive
:
C2
IASLC-TTLC 2023 - 5 days - (New C3)
ROS1 G2032R
Non Small Cell Lung Cancer
ROS1 G2032R
Non Small Cell Lung Cancer
TPX-0005
Sensitive: C3 – Early Trials
IASLC-TTLC 2023 - 5 days (New C3)
TPX-0005
Sensitive
:
C3
IASLC-TTLC 2023 - 5d
TPX-0005
Sensitive: C3 – Early Trials
IASLC-TTLC 2023 - 5 days
TPX-0005
Sensitive
:
C3
IASLC-TTLC 2023 - 5 days - (New C3)
HER-2 positive
Cholangiocarcinoma
HER-2 positive
Cholangiocarcinoma
BI 1810631
Sensitive: C3 – Early Trials
IASLC-TTLC 2023 - 5 days (New C3)
BI 1810631
Sensitive
:
C3
IASLC-TTLC 2023 - 5d
BI 1810631
Sensitive: C3 – Early Trials
IASLC-TTLC 2023 - 5 days
BI 1810631
Sensitive
:
C3
IASLC-TTLC 2023 - 5 days - (New C3)
HER-2 positive
Esophageal Cancer
HER-2 positive
Esophageal Cancer
BI 1810631
Sensitive: C3 – Early Trials
IASLC-TTLC 2023 - 5 days (New C3)
BI 1810631
Sensitive
:
C3
IASLC-TTLC 2023 - 5d
BI 1810631
Sensitive: C3 – Early Trials
IASLC-TTLC 2023 - 5 days
BI 1810631
Sensitive
:
C3
IASLC-TTLC 2023 - 5 days - (New C3)
Chr del(9p) + PD-L1 overexpression
Lung Non-Squamous Non-Small Cell Cancer
Chr del(9p) + PD-L1 overexpression
Lung Non-Squamous Non-Small Cell Cancer
Immunotherapy
Resistant: C3 – Early Trials
IASLC-TTLC 2023 - 5 days (New C3)
Immunotherapy
Resistant
:
C3
IASLC-TTLC 2023 - 5d
Immunotherapy
Resistant: C3 – Early Trials
IASLC-TTLC 2023 - 5 days
Immunotherapy
Resistant
:
C3
IASLC-TTLC 2023 - 5 days - (New C3)
EGFR mutation + TP53 mutation + PTEN mutation
Non Small Cell Lung Cancer
EGFR mutation + TP53 mutation + PTEN mutation
Non Small Cell Lung Cancer
EGFR inhibitor
Resistant: C3 – Early Trials
IASLC-TTLC 2023 - 5 days (New C3)
EGFR inhibitor
Resistant
:
C3
IASLC-TTLC 2023 - 5d
EGFR inhibitor
Resistant: C3 – Early Trials
IASLC-TTLC 2023 - 5 days
EGFR inhibitor
Resistant
:
C3
IASLC-TTLC 2023 - 5 days - (New C3)
EGFR mutation + TP53 mutation + BRCA1 mutation
Non Small Cell Lung Cancer
EGFR mutation + TP53 mutation + BRCA1 mutation
Non Small Cell Lung Cancer
EGFR inhibitor
Resistant: C3 – Early Trials
IASLC-TTLC 2023 - 5 days (New C3)
EGFR inhibitor
Resistant
:
C3
IASLC-TTLC 2023 - 5d
EGFR inhibitor
Resistant: C3 – Early Trials
IASLC-TTLC 2023 - 5 days
EGFR inhibitor
Resistant
:
C3
IASLC-TTLC 2023 - 5 days - (New C3)
EGFR mutation + TP53 mutation + ARID1A mutation
Non Small Cell Lung Cancer
EGFR mutation + TP53 mutation + ARID1A mutation
Non Small Cell Lung Cancer
EGFR inhibitor
Resistant: C3 – Early Trials
IASLC-TTLC 2023 - 5 days (New C3)
EGFR inhibitor
Resistant
:
C3
IASLC-TTLC 2023 - 5d
EGFR inhibitor
Resistant: C3 – Early Trials
IASLC-TTLC 2023 - 5 days
EGFR inhibitor
Resistant
:
C3
IASLC-TTLC 2023 - 5 days - (New C3)
EGFR mutation + TP53 mutation + NF1 mutation
Non Small Cell Lung Cancer
EGFR mutation + TP53 mutation + NF1 mutation
Non Small Cell Lung Cancer
EGFR inhibitor
Resistant: C3 – Early Trials
IASLC-TTLC 2023 - 5 days (New C3)
EGFR inhibitor
Resistant
:
C3
IASLC-TTLC 2023 - 5d
EGFR inhibitor
Resistant: C3 – Early Trials
IASLC-TTLC 2023 - 5 days
EGFR inhibitor
Resistant
:
C3
IASLC-TTLC 2023 - 5 days - (New C3)
EGFR mutation + TP53 mutation + RB1 mutation
Non Small Cell Lung Cancer
EGFR mutation + TP53 mutation + RB1 mutation
Non Small Cell Lung Cancer
EGFR inhibitor
Resistant: C3 – Early Trials
IASLC-TTLC 2023 - 5 days (New C3)
EGFR inhibitor
Resistant
:
C3
IASLC-TTLC 2023 - 5d
EGFR inhibitor
Resistant: C3 – Early Trials
IASLC-TTLC 2023 - 5 days
EGFR inhibitor
Resistant
:
C3
IASLC-TTLC 2023 - 5 days - (New C3)
KEAP1 deletion + KRAS mutation
Lung Non-Squamous Non-Small Cell Cancer
KEAP1 deletion + KRAS mutation
Lung Non-Squamous Non-Small Cell Cancer
Immunotherapy
Resistant: C3 – Early Trials
IASLC-TTLC 2023 - 5 days (New C3)
Immunotherapy
Resistant
:
C3
IASLC-TTLC 2023 - 5d
Immunotherapy
Resistant: C3 – Early Trials
IASLC-TTLC 2023 - 5 days
Immunotherapy
Resistant
:
C3
IASLC-TTLC 2023 - 5 days - (New C3)
STK11 deletion + KRAS mutation
Lung Non-Squamous Non-Small Cell Cancer
STK11 deletion + KRAS mutation
Lung Non-Squamous Non-Small Cell Cancer
Immunotherapy
Resistant: C3 – Early Trials
IASLC-TTLC 2023 - 5 days (New C3)
Immunotherapy
Resistant
:
C3
IASLC-TTLC 2023 - 5d
Immunotherapy
Resistant: C3 – Early Trials
IASLC-TTLC 2023 - 5 days
Immunotherapy
Resistant
:
C3
IASLC-TTLC 2023 - 5 days - (New C3)
EGFR G719A
Non Small Cell Lung Cancer
EGFR G719A
Non Small Cell Lung Cancer
amivantamab-vmjw
Sensitive: C4 – Case Studies
IASLC-TTLC 2023 - 5 days (New C4)
amivantamab-vmjw
Sensitive
:
C4
IASLC-TTLC 2023 - 5d
amivantamab-vmjw
Sensitive: C4 – Case Studies
IASLC-TTLC 2023 - 5 days
amivantamab-vmjw
Sensitive
:
C4
IASLC-TTLC 2023 - 5 days - (New C4)
MET F1200I
Lung Adenocarcinoma
MET F1200I
Lung Adenocarcinoma
TPX-0022
Sensitive: C4 – Case Studies
IASLC-TTLC 2023 - 5 days (New C4)
TPX-0022
Sensitive
:
C4
IASLC-TTLC 2023 - 5d
TPX-0022
Sensitive: C4 – Case Studies
IASLC-TTLC 2023 - 5 days
TPX-0022
Sensitive
:
C4
IASLC-TTLC 2023 - 5 days - (New C4)
MET H1094Y
Lung Adenocarcinoma
MET H1094Y
Lung Adenocarcinoma
TPX-0022
Sensitive: C4 – Case Studies
IASLC-TTLC 2023 - 5 days (New C4)
TPX-0022
Sensitive
:
C4
IASLC-TTLC 2023 - 5d
TPX-0022
Sensitive: C4 – Case Studies
IASLC-TTLC 2023 - 5 days
TPX-0022
Sensitive
:
C4
IASLC-TTLC 2023 - 5 days - (New C4)
SMARCA4 deletion + dMMR/MSI-H + PD-L1 underexpression
Lung Cancer
SMARCA4 deletion + dMMR/MSI-H + PD-L1 underexpression
Lung Cancer
pembrolizumab
Resistant: C4 – Case Studies
IASLC-TTLC 2023 - 5 days (New C4)
pembrolizumab
Resistant
:
C4
IASLC-TTLC 2023 - 5d
pembrolizumab
Resistant: C4 – Case Studies
IASLC-TTLC 2023 - 5 days
pembrolizumab
Resistant
:
C4
IASLC-TTLC 2023 - 5 days - (New C4)
No biomarker
Prostate Cancer
No biomarker
Prostate Cancer
darolutamide
Sensitive: A1 - Approval
Bayer Press Release - 6 days (New B)
darolutamide
Sensitive
:
A1
Bayer Press Release - 6d
darolutamide
Sensitive: A1 - Approval
Bayer Press Release - 6 days
darolutamide
Sensitive
:
A1
Bayer Press Release - 6 days - (New B)
No biomarker
Mantle Cell Lymphoma
No biomarker
Mantle Cell Lymphoma
pirtobrutinib
Sensitive: A1 - Approval
FDA - 6 days (New A1)
pirtobrutinib
Sensitive
:
A1
FDA - 6d
pirtobrutinib
Sensitive: A1 - Approval
FDA - 6 days
pirtobrutinib
Sensitive
:
A1
FDA - 6 days - (New A1)
MGMT unmethylation
Glioma
MGMT unmethylation
Glioma
temozolomide + interferon α-2b
Sensitive: B - Late Trials
JAMA Netw Open - 6 days (New B)
temozolomide + interferon α-2b
Sensitive
:
B
JAMA Netw Open - 6d
temozolomide + interferon α-2b
Sensitive: B - Late Trials
JAMA Netw Open - 6 days
temozolomide + interferon α-2b
Sensitive
:
B
JAMA Netw Open - 6 days - (New B)
ER positive + ESR1 mutation
HER2 Negative Breast Cancer
ER positive + ESR1 mutation
HER2 Negative Breast Cancer
elacestrant
Sensitive: A1 - Approval
FDA - 6 days (New A1)
elacestrant
Sensitive
:
A1
FDA - 6d
elacestrant
Sensitive: A1 - Approval
FDA - 6 days
elacestrant
Sensitive
:
A1
FDA - 6 days - (New A1)
HER-2 positive
HER2 Positive Breast Cancer
HER-2 positive
HER2 Positive Breast Cancer
capecitabine
Sensitive: A2 - Guideline
NCCN - 6 days (New A2)
capecitabine
Sensitive
:
A2
NCCN - 6d
capecitabine
Sensitive: A2 - Guideline
NCCN - 6 days
capecitabine
Sensitive
:
A2
NCCN - 6 days - (New A2)
HER-2 negative
HER2 Negative Breast Cancer
HER-2 negative
HER2 Negative Breast Cancer
pembrolizumab
Sensitive: A2 - Guideline
NCCN - 6 days (New A2)
pembrolizumab
Sensitive
:
A2
NCCN - 6d
pembrolizumab
Sensitive: A2 - Guideline
NCCN - 6 days
pembrolizumab
Sensitive
:
A2
NCCN - 6 days - (New A2)
HER-2 positive
HER2 Positive Breast Cancer
HER-2 positive
HER2 Positive Breast Cancer
dasatinib + lapatinib
Sensitive: D – Preclinical
PLoS One - 6 days (New D)
dasatinib + lapatinib
Sensitive
:
D
PLoS One - 6d
dasatinib + lapatinib
Sensitive: D – Preclinical
PLoS One - 6 days
dasatinib + lapatinib
Sensitive
:
D
PLoS One - 6 days - (New D)
No biomarker
Non Small Cell Lung Cancer
No biomarker
Non Small Cell Lung Cancer
pembrolizumab
Sensitive: A1 - Approval
FDA - 1 week (New A1)
pembrolizumab
Sensitive
:
A1
FDA - 1wk
pembrolizumab
Sensitive: A1 - Approval
FDA - 1 week
pembrolizumab
Sensitive
:
A1
FDA - 1 week - (New A1)
No biomarker
Multiple Myeloma
No biomarker
Multiple Myeloma
lenalidomide + ixazomib
Sensitive: A1 - Approval
Oncology Central - 1 week (New A2)
lenalidomide + ixazomib
Sensitive
:
A1
Oncology Central - 1wk
lenalidomide + ixazomib
Sensitive: A1 - Approval
Oncology Central - 1 week
lenalidomide + ixazomib
Sensitive
:
A1
Oncology Central - 1 week - (New A2)
No biomarker
Follicular Lymphoma
No biomarker
Follicular Lymphoma
mosunetuzumab
Sensitive: A1 - Approval
NCCN - 1 week (New A2)
mosunetuzumab
Sensitive
:
A1
NCCN - 1wk
mosunetuzumab
Sensitive: A1 - Approval
NCCN - 1 week
mosunetuzumab
Sensitive
:
A1
NCCN - 1 week - (New A2)
No biomarker
Marginal Zone Lymphoma
No biomarker
Marginal Zone Lymphoma
acalabrutinib
Sensitive: A2 - Guideline
NCCN - 1 week (New A2)
acalabrutinib
Sensitive
:
A2
NCCN - 1wk
acalabrutinib
Sensitive: A2 - Guideline
NCCN - 1 week
acalabrutinib
Sensitive
:
A2
NCCN - 1 week - (New A2)
No biomarker
Follicular Lymphoma
No biomarker
Follicular Lymphoma
tazemetostat
Sensitive: A2 - Guideline
NCCN - 1 week (New A2)
tazemetostat
Sensitive
:
A2
NCCN - 1wk
tazemetostat
Sensitive: A2 - Guideline
NCCN - 1 week
tazemetostat
Sensitive
:
A2
NCCN - 1 week - (New A2)
HER-2 amplification + RAS wild-type + BRAF wild-type
Colon Cancer
HER-2 amplification + RAS wild-type + BRAF wild-type
Colon Cancer
trastuzumab + tucatinib
Sensitive: A2 - Guideline
NCCN - 1 week (New A2)
trastuzumab + tucatinib
Sensitive
:
A2
NCCN - 1wk
trastuzumab + tucatinib
Sensitive: A2 - Guideline
NCCN - 1 week
trastuzumab + tucatinib
Sensitive
:
A2
NCCN - 1 week - (New A2)
HER-2 overexpression
Endometrial Cancer
HER-2 overexpression
Endometrial Cancer
DB-1303
Sensitive: B - Late Trials
PRNewswire - 1 week (New B)
DB-1303
Sensitive
:
B
PRNewswire - 1wk
DB-1303
Sensitive: B - Late Trials
PRNewswire - 1 week
DB-1303
Sensitive
:
B
PRNewswire - 1 week - (New B)
No biomarker
Biliary Tract Cancer
No biomarker
Biliary Tract Cancer
pembrolizumab
Sensitive: B - Late Trials
Merck (MSD) Press Release - 1 week (New B)
pembrolizumab
Sensitive
:
B
Merck (MSD) Press Release - 1wk
pembrolizumab
Sensitive: B - Late Trials
Merck (MSD) Press Release - 1 week
pembrolizumab
Sensitive
:
B
Merck (MSD) Press Release - 1 week - (New B)
HER-2 negative + PD-L1 expression
Gastroesophageal Junction Adenocarcinoma
HER-2 negative + PD-L1 expression
Gastroesophageal Junction Adenocarcinoma
pembrolizumab
Sensitive: A1 - Approval
Pharmabiz - 1 week (New A1)
pembrolizumab
Sensitive
:
A1
Pharmabiz - 1wk
pembrolizumab
Sensitive: A1 - Approval
Pharmabiz - 1 week
pembrolizumab
Sensitive
:
A1
Pharmabiz - 1 week - (New A1)
BRCA1 mutation
Ovarian Cancer
BRCA1 mutation
Ovarian Cancer
olaparib
Sensitive: A1 - Approval
Anticancer Res - 1 week (New C3)
olaparib
Sensitive
:
A1
Anticancer Res - 1wk
olaparib
Sensitive: A1 - Approval
Anticancer Res - 1 week
olaparib
Sensitive
:
A1
Anticancer Res - 1 week - (New C3)
BRCA2 mutation
Ovarian Cancer
BRCA2 mutation
Ovarian Cancer
olaparib
Sensitive: A1 - Approval
Anticancer Res - 1 week (New C3)
olaparib
Sensitive
:
A1
Anticancer Res - 1wk
olaparib
Sensitive: A1 - Approval
Anticancer Res - 1 week
olaparib
Sensitive
:
A1
Anticancer Res - 1 week - (New C3)
PD-L1 expression
Cervical Cancer
PD-L1 expression
Cervical Cancer
pembrolizumab
Sensitive: A1 - Approval
Pharmabiz - 1 week (New A1)
pembrolizumab
Sensitive
:
A1
Pharmabiz - 1wk
pembrolizumab
Sensitive: A1 - Approval
Pharmabiz - 1 week
pembrolizumab
Sensitive
:
A1
Pharmabiz - 1 week - (New A1)
PD-L1 expression
Esophageal Cancer
PD-L1 expression
Esophageal Cancer
pembrolizumab
Sensitive: A1 - Approval
Pharmabiz - 1 week (New A1)
pembrolizumab
Sensitive
:
A1
Pharmabiz - 1wk
pembrolizumab
Sensitive: A1 - Approval
Pharmabiz - 1 week
pembrolizumab
Sensitive
:
A1
Pharmabiz - 1 week - (New A1)
HER-2 underexpression
Breast Cancer
HER-2 underexpression
Breast Cancer
fam-trastuzumab deruxtecan-nxki
Sensitive: A1 - Approval
Daiichi Sankyo Press Release - 1 week (New A1)
fam-trastuzumab deruxtecan-nxki
Sensitive
:
A1
Daiichi Sankyo Press Release - 1wk
fam-trastuzumab deruxtecan-nxki
Sensitive: A1 - Approval
Daiichi Sankyo Press Release - 1 week
fam-trastuzumab deruxtecan-nxki
Sensitive
:
A1
Daiichi Sankyo Press Release - 1 week - (New A1)
ER positive
Endometrial Cancer
ER positive
Endometrial Cancer
abemaciclib
Sensitive: C2 – Inclusion Criteria
J Clin Oncol - 1 week (New C3)
abemaciclib
Sensitive
:
C2
J Clin Oncol - 1wk
abemaciclib
Sensitive: C2 – Inclusion Criteria
J Clin Oncol - 1 week
abemaciclib
Sensitive
:
C2
J Clin Oncol - 1 week - (New C3)
BRAF V600E
Colorectal Cancer
BRAF V600E
Colorectal Cancer
trametinib + dabrafenib + PDR001
Sensitive: C2 – Inclusion Criteria
Nat Med - 1 week (New C3)
trametinib + dabrafenib + PDR001
Sensitive
:
C2
Nat Med - 1wk
trametinib + dabrafenib + PDR001
Sensitive: C2 – Inclusion Criteria
Nat Med - 1 week
trametinib + dabrafenib + PDR001
Sensitive
:
C2
Nat Med - 1 week - (New C3)
ALK fusion
Lung Adenocarcinoma
ALK fusion
Lung Adenocarcinoma
alectinib
Sensitive: C2 – Inclusion Criteria
Anticancer Drugs - 1 week (New C4)
alectinib
Sensitive
:
C2
Anticancer Drugs - 1wk
alectinib
Sensitive: C2 – Inclusion Criteria
Anticancer Drugs - 1 week
alectinib
Sensitive
:
C2
Anticancer Drugs - 1 week - (New C4)
ROS1 fusion + KRAS G12C
Non Small Cell Lung Cancer
ROS1 fusion + KRAS G12C
Non Small Cell Lung Cancer
entrectinib
Resistant: C4 – Case Studies
NPJ Precis Oncol - 1 week (New C4)
entrectinib
Resistant
:
C4
NPJ Precis Oncol - 1wk
entrectinib
Resistant: C4 – Case Studies
NPJ Precis Oncol - 1 week
entrectinib
Resistant
:
C4
NPJ Precis Oncol - 1 week - (New C4)
EML4-ALK fusion
Lung Adenocarcinoma
EML4-ALK fusion
Lung Adenocarcinoma
alectinib
Sensitive: C4 – Case Studies
Anticancer Drugs - 1 week (New C4)
alectinib
Sensitive
:
C4
Anticancer Drugs - 1wk
alectinib
Sensitive: C4 – Case Studies
Anticancer Drugs - 1 week
alectinib
Sensitive
:
C4
Anticancer Drugs - 1 week - (New C4)
RET fusion + TP53 mutation
HER2 Positive Breast Cancer
RET fusion + TP53 mutation
HER2 Positive Breast Cancer
pyrotinib
Resistant: C4 – Case Studies
Anticancer Drugs - 1 week (New C4)
pyrotinib
Resistant
:
C4
Anticancer Drugs - 1wk
pyrotinib
Resistant: C4 – Case Studies
Anticancer Drugs - 1 week
pyrotinib
Resistant
:
C4
Anticancer Drugs - 1 week - (New C4)
TMB-H + PD-L1 expression
Lung Cancer
TMB-H + PD-L1 expression
Lung Cancer
pembrolizumab
Sensitive: C4 – Case Studies
Medicine (Baltimore) - 1 week (New C4)
pembrolizumab
Sensitive
:
C4
Medicine (Baltimore) - 1wk
pembrolizumab
Sensitive: C4 – Case Studies
Medicine (Baltimore) - 1 week
pembrolizumab
Sensitive
:
C4
Medicine (Baltimore) - 1 week - (New C4)
ALK positive
Non Small Cell Lung Cancer
ALK positive
Non Small Cell Lung Cancer
crizotinib
Sensitive: A1 - Approval
Cancer Manag Res - 2 weeks (New C3)
crizotinib
Sensitive
:
A1
Cancer Manag Res - 2wk
crizotinib
Sensitive: A1 - Approval
Cancer Manag Res - 2 weeks
crizotinib
Sensitive
:
A1
Cancer Manag Res - 2 weeks - (New C3)
No biomarker
Hepatocellular Cancer
No biomarker
Hepatocellular Cancer
bevacizumab + atezolizumab
Sensitive: A1 - Approval
Businesswire - 2 weeks (New B)
bevacizumab + atezolizumab
Sensitive
:
A1
Businesswire - 2wk
bevacizumab + atezolizumab
Sensitive: A1 - Approval
Businesswire - 2 weeks
bevacizumab + atezolizumab
Sensitive
:
A1
Businesswire - 2 weeks - (New B)
No biomarker
Hepatocellular Cancer
No biomarker
Hepatocellular Cancer
sorafenib
Sensitive: A1 - Approval
ASCO-GI 2023 - 2 weeks (New B)
sorafenib
Sensitive
:
A1
ASCO-GI 2023 - 2wk
sorafenib
Sensitive: A1 - Approval
ASCO-GI 2023 - 2 weeks
sorafenib
Sensitive
:
A1
ASCO-GI 2023 - 2 weeks - (New B)
No biomarker
Colorectal Cancer
No biomarker
Colorectal Cancer
fruquintinib
Sensitive: A1 - Approval
ASCO-GI 2023 - 2 weeks (New B)
fruquintinib
Sensitive
:
A1
ASCO-GI 2023 - 2wk
fruquintinib
Sensitive: A1 - Approval
ASCO-GI 2023 - 2 weeks
fruquintinib
Sensitive
:
A1
ASCO-GI 2023 - 2 weeks - (New B)
No biomarker
Small Cell Lung Cancer
No biomarker
Small Cell Lung Cancer
serplulimab
Sensitive: A1 - Approval
Henlius Press Release - 2 weeks (New A1)
serplulimab
Sensitive
:
A1
Henlius Press Release - 2wk
serplulimab
Sensitive: A1 - Approval
Henlius Press Release - 2 weeks
serplulimab
Sensitive
:
A1
Henlius Press Release - 2 weeks - (New A1)
No biomarker
Lung Non-Small Cell Squamous Cancer
No biomarker
Lung Non-Small Cell Squamous Cancer
penpulimab
Sensitive: A1 - Approval
Akeso Biopharma Press Release - 2 weeks (New A1)
penpulimab
Sensitive
:
A1
Akeso Biopharma Press Release - 2wk
penpulimab
Sensitive: A1 - Approval
Akeso Biopharma Press Release - 2 weeks
penpulimab
Sensitive
:
A1
Akeso Biopharma Press Release - 2 weeks - (New A1)
BRAF V600E
Colorectal Cancer
BRAF V600E
Colorectal Cancer
cetuximab + trametinib + dabrafenib
Sensitive: A2 - Guideline
ASCO-GI 2023 - 2 weeks (New C3)
cetuximab + trametinib + dabrafenib
Sensitive
:
A2
ASCO-GI 2023 - 2wk
cetuximab + trametinib + dabrafenib
Sensitive: A2 - Guideline
ASCO-GI 2023 - 2 weeks
cetuximab + trametinib + dabrafenib
Sensitive
:
A2
ASCO-GI 2023 - 2 weeks - (New C3)
HR positive
HER2 Negative Breast Cancer
HR positive
HER2 Negative Breast Cancer
CDK6 inhibitor
Sensitive: B - Late Trials
Endokrynol Pol - 2 weeks (New C3)
CDK6 inhibitor
Sensitive
:
B
Endokrynol Pol - 2wk
CDK6 inhibitor
Sensitive: B - Late Trials
Endokrynol Pol - 2 weeks
CDK6 inhibitor
Sensitive
:
B
Endokrynol Pol - 2 weeks - (New C3)
HR positive
HER2 Negative Breast Cancer
HR positive
HER2 Negative Breast Cancer
CDK4 inhibitor
Sensitive: B - Late Trials
Endokrynol Pol - 2 weeks (New C3)
CDK4 inhibitor
Sensitive
:
B
Endokrynol Pol - 2wk
CDK4 inhibitor
Sensitive: B - Late Trials
Endokrynol Pol - 2 weeks
CDK4 inhibitor
Sensitive
:
B
Endokrynol Pol - 2 weeks - (New C3)
KIT exon 17 mutation
Gastrointestinal Stromal Tumor
KIT exon 17 mutation
Gastrointestinal Stromal Tumor
ripretinib
Sensitive: B - Late Trials
ASCO-GI 2023 - 2 weeks (New C3)
ripretinib
Sensitive
:
B
ASCO-GI 2023 - 2wk
ripretinib
Sensitive: B - Late Trials
ASCO-GI 2023 - 2 weeks
ripretinib
Sensitive
:
B
ASCO-GI 2023 - 2 weeks - (New C3)
KIT exon 11 mutation
Gastrointestinal Stromal Tumor
KIT exon 11 mutation
Gastrointestinal Stromal Tumor
ripretinib
Sensitive: B - Late Trials
ASCO-GI 2023 - 2 weeks (New C3)
ripretinib
Sensitive
:
B
ASCO-GI 2023 - 2wk
ripretinib
Sensitive: B - Late Trials
ASCO-GI 2023 - 2 weeks
ripretinib
Sensitive
:
B
ASCO-GI 2023 - 2 weeks - (New C3)
PD-L1 expression
Gastric Cancer
PD-L1 expression
Gastric Cancer
tislelizumab
Sensitive: B - Late Trials
ASCO-GI 2023 - 2 weeks (New B)
tislelizumab
Sensitive
:
B
ASCO-GI 2023 - 2wk
tislelizumab
Sensitive: B - Late Trials
ASCO-GI 2023 - 2 weeks
tislelizumab
Sensitive
:
B
ASCO-GI 2023 - 2 weeks - (New B)
PD-L1 expression
Gastroesophageal Junction Adenocarcinoma
PD-L1 expression
Gastroesophageal Junction Adenocarcinoma
tislelizumab
Sensitive: B - Late Trials
ASCO-GI 2023 - 2 weeks (New B)
tislelizumab
Sensitive
:
B
ASCO-GI 2023 - 2wk
tislelizumab
Sensitive: B - Late Trials
ASCO-GI 2023 - 2 weeks
tislelizumab
Sensitive
:
B
ASCO-GI 2023 - 2 weeks - (New B)
KIT exon 18 mutation
Gastrointestinal Stromal Tumor
KIT exon 18 mutation
Gastrointestinal Stromal Tumor
ripretinib
Sensitive: B - Late Trials
ASCO-GI 2023 - 2 weeks (New C3)
ripretinib
Sensitive
:
B
ASCO-GI 2023 - 2wk
ripretinib
Sensitive: B - Late Trials
ASCO-GI 2023 - 2 weeks
ripretinib
Sensitive
:
B
ASCO-GI 2023 - 2 weeks - (New C3)
No biomarker
Non Small Cell Lung Cancer
No biomarker
Non Small Cell Lung Cancer
toripalimab
Sensitive: B - Late Trials
BioSpace - 2 weeks (New B)
toripalimab
Sensitive
:
B
BioSpace - 2wk
toripalimab
Sensitive: B - Late Trials
BioSpace - 2 weeks
toripalimab
Sensitive
:
B
BioSpace - 2 weeks - (New B)
CLDN18.2 positive + HER-2 negative
Gastroesophageal Junction Adenocarcinoma
CLDN18.2 positive + HER-2 negative
Gastroesophageal Junction Adenocarcinoma
IMAB362
Sensitive: B - Late Trials
ASCO-GI 2023 - 2 weeks (New B)
IMAB362
Sensitive
:
B
ASCO-GI 2023 - 2wk
IMAB362
Sensitive: B - Late Trials
ASCO-GI 2023 - 2 weeks
IMAB362
Sensitive
:
B
ASCO-GI 2023 - 2 weeks - (New B)
CLDN18.2 positive + HER-2 negative
Gastric Cancer
CLDN18.2 positive + HER-2 negative
Gastric Cancer
IMAB362
Sensitive: B - Late Trials
ASCO-GI 2023 - 2 weeks (New B)
IMAB362
Sensitive
:
B
ASCO-GI 2023 - 2wk
IMAB362
Sensitive: B - Late Trials
ASCO-GI 2023 - 2 weeks
IMAB362
Sensitive
:
B
ASCO-GI 2023 - 2 weeks - (New B)
EGFR T790M
Non Small Cell Lung Cancer
EGFR T790M
Non Small Cell Lung Cancer
osimertinib
Sensitive: A1 - Approval
Future Oncol - 2 weeks (New B)
osimertinib
Sensitive
:
A1
Future Oncol - 2wk
osimertinib
Sensitive: A1 - Approval
Future Oncol - 2 weeks
osimertinib
Sensitive
:
A1
Future Oncol - 2 weeks - (New B)
ALK positive
Non Small Cell Lung Cancer
ALK positive
Non Small Cell Lung Cancer
alectinib
Sensitive: A1 - Approval
Cancer Manag Res - 2 weeks (New C3)
alectinib
Sensitive
:
A1
Cancer Manag Res - 2wk
alectinib
Sensitive: A1 - Approval
Cancer Manag Res - 2 weeks
alectinib
Sensitive
:
A1
Cancer Manag Res - 2 weeks - (New C3)
PD-L1 expression
Esophageal Squamous Cell Carcinoma
PD-L1 expression
Esophageal Squamous Cell Carcinoma
nivolumab
Sensitive: A1 - Approval
ASCO-GI 2023 - 2 weeks (New B)
nivolumab
Sensitive
:
A1
ASCO-GI 2023 - 2wk
nivolumab
Sensitive: A1 - Approval
ASCO-GI 2023 - 2 weeks
nivolumab
Sensitive
:
A1
ASCO-GI 2023 - 2 weeks - (New B)
MSI-H/dMMR
Colorectal Cancer
MSI-H/dMMR
Colorectal Cancer
pembrolizumab
Sensitive: A1 - Approval
ASCO-GI 2023 - 2 weeks (New C3)
pembrolizumab
Sensitive
:
A1
ASCO-GI 2023 - 2wk
pembrolizumab
Sensitive: A1 - Approval
ASCO-GI 2023 - 2 weeks
pembrolizumab
Sensitive
:
A1
ASCO-GI 2023 - 2 weeks - (New C3)
BRAF V600E
Colorectal Cancer
BRAF V600E
Colorectal Cancer
cetuximab + encorafenib
Sensitive: A1 - Approval
ASCO-GI 2023 - 2 weeks (New C3)
cetuximab + encorafenib
Sensitive
:
A1
ASCO-GI 2023 - 2wk
cetuximab + encorafenib
Sensitive: A1 - Approval
ASCO-GI 2023 - 2 weeks
cetuximab + encorafenib
Sensitive
:
A1
ASCO-GI 2023 - 2 weeks - (New C3)
PD-L1 expression
Squamous Cell Carcinoma of Head and Neck
PD-L1 expression
Squamous Cell Carcinoma of Head and Neck
pembrolizumab
Sensitive: A1 - Approval
ASCO.org - 2 weeks (New A2)
pembrolizumab
Sensitive
:
A1
ASCO.org - 2wk
pembrolizumab
Sensitive: A1 - Approval
ASCO.org - 2 weeks
pembrolizumab
Sensitive
:
A1
ASCO.org - 2 weeks - (New A2)
HER-2 negative + PD-L1 expression
Gastroesophageal Junction Adenocarcinoma
HER-2 negative + PD-L1 expression
Gastroesophageal Junction Adenocarcinoma
nivolumab
Sensitive: A1 - Approval
ASCO-GI 2023 - 2 weeks (New C3)
nivolumab
Sensitive
:
A1
ASCO-GI 2023 - 2wk
nivolumab
Sensitive: A1 - Approval
ASCO-GI 2023 - 2 weeks
nivolumab
Sensitive
:
A1
ASCO-GI 2023 - 2 weeks - (New C3)
HER-2 negative + PD-L1 expression
Gastric Cancer
HER-2 negative + PD-L1 expression
Gastric Cancer
nivolumab
Sensitive: A1 - Approval
ASCO-GI 2023 - 2 weeks (New C3)
nivolumab
Sensitive
:
A1
ASCO-GI 2023 - 2wk
nivolumab
Sensitive: A1 - Approval
ASCO-GI 2023 - 2 weeks
nivolumab
Sensitive
:
A1
ASCO-GI 2023 - 2 weeks - (New C3)
IDH1 mutation
Acute Myelogenous Leukemia
IDH1 mutation
Acute Myelogenous Leukemia
olutasidenib
Sensitive: A1 - Approval
NCCN - 2 weeks (New A2)
olutasidenib
Sensitive
:
A1
NCCN - 2wk
olutasidenib
Sensitive: A1 - Approval
NCCN - 2 weeks
olutasidenib
Sensitive
:
A1
NCCN - 2 weeks - (New A2)
EGFR exon 20 insertion
Non Small Cell Lung Cancer
EGFR exon 20 insertion
Non Small Cell Lung Cancer
amivantamab-vmjw
Sensitive: A1 - Approval
Adv Ther - 2 weeks (New C3)
amivantamab-vmjw
Sensitive
:
A1
Adv Ther - 2wk
amivantamab-vmjw
Sensitive: A1 - Approval
Adv Ther - 2 weeks
amivantamab-vmjw
Sensitive
:
A1
Adv Ther - 2 weeks - (New C3)
ALK positive
Non Small Cell Lung Cancer
ALK positive
Non Small Cell Lung Cancer
ceritinib
Sensitive: A1 - Approval
Cancer Manag Res - 2 weeks (New C3)
ceritinib
Sensitive
:
A1
Cancer Manag Res - 2wk
ceritinib
Sensitive: A1 - Approval
Cancer Manag Res - 2 weeks
ceritinib
Sensitive
:
A1
Cancer Manag Res - 2 weeks - (New C3)
FGFR2 rearrangement
Cholangiocarcinoma
FGFR2 rearrangement
Cholangiocarcinoma
futibatinib
Sensitive: A1 - Approval
N Engl J Med - 2 weeks (New C3)
futibatinib
Sensitive
:
A1
N Engl J Med - 2wk
futibatinib
Sensitive: A1 - Approval
N Engl J Med - 2 weeks
futibatinib
Sensitive
:
A1
N Engl J Med - 2 weeks - (New C3)
FGFR2 fusion
Cholangiocarcinoma
FGFR2 fusion
Cholangiocarcinoma
futibatinib
Sensitive: A1 - Approval
N Engl J Med - 2 weeks (New C3)
futibatinib
Sensitive
:
A1
N Engl J Med - 2wk
futibatinib
Sensitive: A1 - Approval
N Engl J Med - 2 weeks
futibatinib
Sensitive
:
A1
N Engl J Med - 2 weeks - (New C3)
HER-2 negative + PD-L1 expression
Esophageal Adenocarcinoma
HER-2 negative + PD-L1 expression
Esophageal Adenocarcinoma
nivolumab
Sensitive: A1 - Approval
ASCO-GI 2023 - 2 weeks (New C3)
nivolumab
Sensitive
:
A1
ASCO-GI 2023 - 2wk
nivolumab
Sensitive: A1 - Approval
ASCO-GI 2023 - 2 weeks
nivolumab
Sensitive
:
A1
ASCO-GI 2023 - 2 weeks - (New C3)
PD-L1 expression
Esophageal Squamous Cell Carcinoma
PD-L1 expression
Esophageal Squamous Cell Carcinoma
nivolumab + ipilimumab
Sensitive: A1 - Approval
ASCO-GI 2023 - 2 weeks (New B)
nivolumab + ipilimumab
Sensitive
:
A1
ASCO-GI 2023 - 2wk
nivolumab + ipilimumab
Sensitive: A1 - Approval
ASCO-GI 2023 - 2 weeks
nivolumab + ipilimumab
Sensitive
:
A1
ASCO-GI 2023 - 2 weeks - (New B)
RAS wild-type + HER-2 positive
Colorectal Cancer
RAS wild-type + HER-2 positive
Colorectal Cancer
trastuzumab + tucatinib
Sensitive: A1 - Approval
FDA - 2 weeks (New A1)
trastuzumab + tucatinib
Sensitive
:
A1
FDA - 2wk
trastuzumab + tucatinib
Sensitive: A1 - Approval
FDA - 2 weeks
trastuzumab + tucatinib
Sensitive
:
A1
FDA - 2 weeks - (New A1)
EGFR exon 19 deletion
Lung Adenocarcinoma
EGFR exon 19 deletion
Lung Adenocarcinoma
osimertinib
Sensitive: C1 - Off-label
Cancer Lett - 2 weeks (New D)
osimertinib
Sensitive
:
C1
Cancer Lett - 2wk
osimertinib
Sensitive: C1 - Off-label
Cancer Lett - 2 weeks
osimertinib
Sensitive
:
C1
Cancer Lett - 2 weeks - (New D)
PD-L1 expression
Biliary Tract Cancer
PD-L1 expression
Biliary Tract Cancer
nivolumab
Sensitive: C1 - Off-label
ASCO-GI 2023 - 2 weeks (New C3)
nivolumab
Sensitive
:
C1
ASCO-GI 2023 - 2wk
nivolumab
Sensitive: C1 - Off-label
ASCO-GI 2023 - 2 weeks
nivolumab
Sensitive
:
C1
ASCO-GI 2023 - 2 weeks - (New C3)
HER-2 positive
Gastric Cancer
HER-2 positive
Gastric Cancer
pyrotinib + dalpiciclib
Sensitive: C2 – Inclusion Criteria
ASCO-GI 2023 - 2 weeks (New C3)
pyrotinib + dalpiciclib
Sensitive
:
C2
ASCO-GI 2023 - 2wk
pyrotinib + dalpiciclib
Sensitive: C2 – Inclusion Criteria
ASCO-GI 2023 - 2 weeks
pyrotinib + dalpiciclib
Sensitive
:
C2
ASCO-GI 2023 - 2 weeks - (New C3)
MSI-H/dMMR
Colorectal Cancer
MSI-H/dMMR
Colorectal Cancer
regorafenib
Sensitive: C2 – Inclusion Criteria
ASCO-GI 2023 - 2 weeks (New C3)
regorafenib
Sensitive
:
C2
ASCO-GI 2023 - 2wk
regorafenib
Sensitive: C2 – Inclusion Criteria
ASCO-GI 2023 - 2 weeks
regorafenib
Sensitive
:
C2
ASCO-GI 2023 - 2 weeks - (New C3)
POLE mutation
Solid Tumor
POLE mutation
Solid Tumor
toripalimab
Sensitive: C2 – Inclusion Criteria
ASCO-GI 2023 - 2 weeks (New C3)
toripalimab
Sensitive
:
C2
ASCO-GI 2023 - 2wk
toripalimab
Sensitive: C2 – Inclusion Criteria
ASCO-GI 2023 - 2 weeks
toripalimab
Sensitive
:
C2
ASCO-GI 2023 - 2 weeks - (New C3)
POLD1 mutation
Solid Tumor
POLD1 mutation
Solid Tumor
toripalimab
Sensitive: C2 – Inclusion Criteria
ASCO-GI 2023 - 2 weeks (New C3)
toripalimab
Sensitive
:
C2
ASCO-GI 2023 - 2wk
toripalimab
Sensitive: C2 – Inclusion Criteria
ASCO-GI 2023 - 2 weeks
toripalimab
Sensitive
:
C2
ASCO-GI 2023 - 2 weeks - (New C3)
HER-2 negative
Gastroesophageal Junction Adenocarcinoma
HER-2 negative
Gastroesophageal Junction Adenocarcinoma
camrelizumab + rivoceranib
Sensitive: C2 – Inclusion Criteria
ASCO-GI 2023 - 2 weeks (New C3)
camrelizumab + rivoceranib
Sensitive
:
C2
ASCO-GI 2023 - 2wk
camrelizumab + rivoceranib
Sensitive: C2 – Inclusion Criteria
ASCO-GI 2023 - 2 weeks
camrelizumab + rivoceranib
Sensitive
:
C2
ASCO-GI 2023 - 2 weeks - (New C3)
HER-2 negative
Gastric Cancer
HER-2 negative
Gastric Cancer
camrelizumab + rivoceranib
Sensitive: C2 – Inclusion Criteria
ASCO-GI 2023 - 2 weeks (New C3)
camrelizumab + rivoceranib
Sensitive
:
C2
ASCO-GI 2023 - 2wk
camrelizumab + rivoceranib
Sensitive: C2 – Inclusion Criteria
ASCO-GI 2023 - 2 weeks
camrelizumab + rivoceranib
Sensitive
:
C2
ASCO-GI 2023 - 2 weeks - (New C3)
HER-2 overexpression
Gastroesophageal Junction Adenocarcinoma
HER-2 overexpression
Gastroesophageal Junction Adenocarcinoma
Her-VAXX
Sensitive: C2 – Inclusion Criteria
ASCO-GI 2023 - 2 weeks (New C3)
Her-VAXX
Sensitive
:
C2
ASCO-GI 2023 - 2wk
Her-VAXX
Sensitive: C2 – Inclusion Criteria
ASCO-GI 2023 - 2 weeks
Her-VAXX
Sensitive
:
C2
ASCO-GI 2023 - 2 weeks - (New C3)
FGFR2 fusion
Cholangiocarcinoma
FGFR2 fusion
Cholangiocarcinoma
ICP-192
Sensitive: C2 – Inclusion Criteria
ASCO-GI 2023 - 2 weeks (New C3)
ICP-192
Sensitive
:
C2
ASCO-GI 2023 - 2wk
ICP-192
Sensitive: C2 – Inclusion Criteria
ASCO-GI 2023 - 2 weeks
ICP-192
Sensitive
:
C2
ASCO-GI 2023 - 2 weeks - (New C3)
FGFR2 mutation
Cholangiocarcinoma
FGFR2 mutation
Cholangiocarcinoma
TT-00420
Sensitive: C2 – Inclusion Criteria
ASCO-GI 2023 - 2 weeks (New C3)
TT-00420
Sensitive
:
C2
ASCO-GI 2023 - 2wk
TT-00420
Sensitive: C2 – Inclusion Criteria
ASCO-GI 2023 - 2 weeks
TT-00420
Sensitive
:
C2
ASCO-GI 2023 - 2 weeks - (New C3)
KRAS wild-type
Colorectal Cancer
KRAS wild-type
Colorectal Cancer
cetuximab
Sensitive: C2 – Inclusion Criteria
ASCO-GI 2023 - 2 weeks (New C3)
cetuximab
Sensitive
:
C2
ASCO-GI 2023 - 2wk
cetuximab
Sensitive: C2 – Inclusion Criteria
ASCO-GI 2023 - 2 weeks
cetuximab
Sensitive
:
C2
ASCO-GI 2023 - 2 weeks - (New C3)
KRAS wild-type
Colorectal Cancer
KRAS wild-type
Colorectal Cancer
bevacizumab
Sensitive: C2 – Inclusion Criteria
ASCO-GI 2023 - 2 weeks (New C3)
bevacizumab
Sensitive
:
C2
ASCO-GI 2023 - 2wk
bevacizumab
Sensitive: C2 – Inclusion Criteria
ASCO-GI 2023 - 2 weeks
bevacizumab
Sensitive
:
C2
ASCO-GI 2023 - 2 weeks - (New C3)
BRAF wild-type
Colorectal Cancer
BRAF wild-type
Colorectal Cancer
anlotinib
Sensitive: C2 – Inclusion Criteria
ASCO-GI 2023 - 2 weeks (New C3)
anlotinib
Sensitive
:
C2
ASCO-GI 2023 - 2wk
anlotinib
Sensitive: C2 – Inclusion Criteria
ASCO-GI 2023 - 2 weeks
anlotinib
Sensitive
:
C2
ASCO-GI 2023 - 2 weeks - (New C3)
HER-2 overexpression
Gastric Cancer
HER-2 overexpression
Gastric Cancer
Her-VAXX
Sensitive: C2 – Inclusion Criteria
ASCO-GI 2023 - 2 weeks (New C3)
Her-VAXX
Sensitive
:
C2
ASCO-GI 2023 - 2wk
Her-VAXX
Sensitive: C2 – Inclusion Criteria
ASCO-GI 2023 - 2 weeks
Her-VAXX
Sensitive
:
C2
ASCO-GI 2023 - 2 weeks - (New C3)
MSI-H/dMMR
Gastric Cancer
MSI-H/dMMR
Gastric Cancer
durvalumab + tremelimumab
Sensitive: C2 – Inclusion Criteria
ASCO-GI 2023 - 2 weeks (New C3)
durvalumab + tremelimumab
Sensitive
:
C2
ASCO-GI 2023 - 2wk
durvalumab + tremelimumab
Sensitive: C2 – Inclusion Criteria
ASCO-GI 2023 - 2 weeks
durvalumab + tremelimumab
Sensitive
:
C2
ASCO-GI 2023 - 2 weeks - (New C3)
CLDN18.2 positive
Gastric Cancer
CLDN18.2 positive
Gastric Cancer
AB011
Sensitive: C2 – Inclusion Criteria
ASCO-GI 2023 - 2 weeks (New C3)
AB011
Sensitive
:
C2
ASCO-GI 2023 - 2wk
AB011
Sensitive: C2 – Inclusion Criteria
ASCO-GI 2023 - 2 weeks
AB011
Sensitive
:
C2
ASCO-GI 2023 - 2 weeks - (New C3)
CLDN18.2 positive
Gastroesophageal Junction Adenocarcinoma
CLDN18.2 positive
Gastroesophageal Junction Adenocarcinoma
CMG901
Sensitive: C2 – Inclusion Criteria
ASCO-GI 2023 - 2 weeks (New C3)
CMG901
Sensitive
:
C2
ASCO-GI 2023 - 2wk
CMG901
Sensitive: C2 – Inclusion Criteria
ASCO-GI 2023 - 2 weeks
CMG901
Sensitive
:
C2
ASCO-GI 2023 - 2 weeks - (New C3)
CLDN18.2 positive
Gastric Cancer
CLDN18.2 positive
Gastric Cancer
CMG901
Sensitive: C2 – Inclusion Criteria
ASCO-GI 2023 - 2 weeks (New C3)
CMG901
Sensitive
:
C2
ASCO-GI 2023 - 2wk
CMG901
Sensitive: C2 – Inclusion Criteria
ASCO-GI 2023 - 2 weeks
CMG901
Sensitive
:
C2
ASCO-GI 2023 - 2 weeks - (New C3)
MDM2 amplification
Cholangiocarcinoma
MDM2 amplification
Cholangiocarcinoma
BI 907828
Sensitive: C2 – Inclusion Criteria
ASCO-GI 2023 - 2 weeks (New C3)
BI 907828
Sensitive
:
C2
ASCO-GI 2023 - 2wk
BI 907828
Sensitive: C2 – Inclusion Criteria
ASCO-GI 2023 - 2 weeks
BI 907828
Sensitive
:
C2
ASCO-GI 2023 - 2 weeks - (New C3)
MDM2 amplification
Biliary Tract Cancer
MDM2 amplification
Biliary Tract Cancer
BI 907828
Sensitive: C2 – Inclusion Criteria
ASCO-GI 2023 - 2 weeks (New C3)
BI 907828
Sensitive
:
C2
ASCO-GI 2023 - 2wk
BI 907828
Sensitive: C2 – Inclusion Criteria
ASCO-GI 2023 - 2 weeks
BI 907828
Sensitive
:
C2
ASCO-GI 2023 - 2 weeks - (New C3)
FGFR2 fusion
Cholangiocarcinoma
FGFR2 fusion
Cholangiocarcinoma
TT-00420
Sensitive: C2 – Inclusion Criteria
ASCO-GI 2023 - 2 weeks (New C3)
TT-00420
Sensitive
:
C2
ASCO-GI 2023 - 2wk
TT-00420
Sensitive: C2 – Inclusion Criteria
ASCO-GI 2023 - 2 weeks
TT-00420
Sensitive
:
C2
ASCO-GI 2023 - 2 weeks - (New C3)
MSI-H/dMMR
Colorectal Cancer
MSI-H/dMMR
Colorectal Cancer
Immunotherapy
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks (New C3)
Immunotherapy
Sensitive
:
C3
ASCO-GI 2023 - 2wk
Immunotherapy
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks
Immunotherapy
Sensitive
:
C3
ASCO-GI 2023 - 2 weeks - (New C3)
HER-2 expression
Gastroesophageal Cancer
HER-2 expression
Gastroesophageal Cancer
ZW25
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks (New C3)
ZW25
Sensitive
:
C3
ASCO-GI 2023 - 2wk
ZW25
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks
ZW25
Sensitive
:
C3
ASCO-GI 2023 - 2 weeks - (New C3)
EREG overexpression + AREG overexpression
Colorectal Cancer
EREG overexpression + AREG overexpression
Colorectal Cancer
panitumumab
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks (New C3)
panitumumab
Sensitive
:
C3
ASCO-GI 2023 - 2wk
panitumumab
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks
panitumumab
Sensitive
:
C3
ASCO-GI 2023 - 2 weeks - (New C3)
BRAF V600E
Colorectal Cancer
BRAF V600E
Colorectal Cancer
erlotinib + vemurafenib
Sensitive: C3 – Early Trials
Clin Cancer Res - 2 weeks (New C3)
erlotinib + vemurafenib
Sensitive
:
C3
Clin Cancer Res - 2wk
erlotinib + vemurafenib
Sensitive: C3 – Early Trials
Clin Cancer Res - 2 weeks
erlotinib + vemurafenib
Sensitive
:
C3
Clin Cancer Res - 2 weeks - (New C3)
RAS wild-type
Colorectal Cancer
RAS wild-type
Colorectal Cancer
anlotinib
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks (New C3)
anlotinib
Sensitive
:
C3
ASCO-GI 2023 - 2wk
anlotinib
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks
anlotinib
Sensitive
:
C3
ASCO-GI 2023 - 2 weeks - (New C3)
RAS wild-type
Colorectal Cancer
RAS wild-type
Colorectal Cancer
cetuximab + tislelizumab
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks (New C3)
cetuximab + tislelizumab
Sensitive
:
C3
ASCO-GI 2023 - 2wk
cetuximab + tislelizumab
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks
cetuximab + tislelizumab
Sensitive
:
C3
ASCO-GI 2023 - 2 weeks - (New C3)
BRAF wild-type + HER-2 positive
Colorectal Cancer
BRAF wild-type + HER-2 positive
Colorectal Cancer
trastuzumab + pertuzumab
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks (New C3)
trastuzumab + pertuzumab
Sensitive
:
C3
ASCO-GI 2023 - 2wk
trastuzumab + pertuzumab
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks
trastuzumab + pertuzumab
Sensitive
:
C3
ASCO-GI 2023 - 2 weeks - (New C3)
RAS wild-type + HER-2 positive
Colorectal Cancer
RAS wild-type + HER-2 positive
Colorectal Cancer
trastuzumab + pertuzumab
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks (New C3)
trastuzumab + pertuzumab
Sensitive
:
C3
ASCO-GI 2023 - 2wk
trastuzumab + pertuzumab
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks
trastuzumab + pertuzumab
Sensitive
:
C3
ASCO-GI 2023 - 2 weeks - (New C3)
MSI-H/dMMR
Gastroesophageal Junction Adenocarcinoma
MSI-H/dMMR
Gastroesophageal Junction Adenocarcinoma
durvalumab + tremelimumab
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks (New C3)
durvalumab + tremelimumab
Sensitive
:
C3
ASCO-GI 2023 - 2wk
durvalumab + tremelimumab
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks
durvalumab + tremelimumab
Sensitive
:
C3
ASCO-GI 2023 - 2 weeks - (New C3)
CLDN18.2 positive
Gastroesophageal Junction Adenocarcinoma
CLDN18.2 positive
Gastroesophageal Junction Adenocarcinoma
AB011
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks (New C3)
AB011
Sensitive
:
C3
ASCO-GI 2023 - 2wk
AB011
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks
AB011
Sensitive
:
C3
ASCO-GI 2023 - 2 weeks - (New C3)
PD-L1 expression
Solid Tumor
PD-L1 expression
Solid Tumor
pembrolizumab + MK-4280
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks (New C3)
pembrolizumab + MK-4280
Sensitive
:
C3
ASCO-GI 2023 - 2wk
pembrolizumab + MK-4280
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks
pembrolizumab + MK-4280
Sensitive
:
C3
ASCO-GI 2023 - 2 weeks - (New C3)
TMB-H
Gastric Cancer
TMB-H
Gastric Cancer
durvalumab + tremelimumab
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks (New C3)
durvalumab + tremelimumab
Sensitive
:
C3
ASCO-GI 2023 - 2wk
durvalumab + tremelimumab
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks
durvalumab + tremelimumab
Sensitive
:
C3
ASCO-GI 2023 - 2 weeks - (New C3)
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
camrelizumab + pyrotinib
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks (New C3)
camrelizumab + pyrotinib
Sensitive
:
C3
ASCO-GI 2023 - 2wk
camrelizumab + pyrotinib
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks
camrelizumab + pyrotinib
Sensitive
:
C3
ASCO-GI 2023 - 2 weeks - (New C3)
HER-2 positive
Gastric Cancer
HER-2 positive
Gastric Cancer
camrelizumab + pyrotinib
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks (New C3)
camrelizumab + pyrotinib
Sensitive
:
C3
ASCO-GI 2023 - 2wk
camrelizumab + pyrotinib
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks
camrelizumab + pyrotinib
Sensitive
:
C3
ASCO-GI 2023 - 2 weeks - (New C3)
HER-2 negative
Gastroesophageal Junction Adenocarcinoma
HER-2 negative
Gastroesophageal Junction Adenocarcinoma
anlotinib + APL-502
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks (New C3)
anlotinib + APL-502
Sensitive
:
C3
ASCO-GI 2023 - 2wk
anlotinib + APL-502
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks
anlotinib + APL-502
Sensitive
:
C3
ASCO-GI 2023 - 2 weeks - (New C3)
HER-2 negative
Gastric Cancer
HER-2 negative
Gastric Cancer
anlotinib + APL-502
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks (New C3)
anlotinib + APL-502
Sensitive
:
C3
ASCO-GI 2023 - 2wk
anlotinib + APL-502
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks
anlotinib + APL-502
Sensitive
:
C3
ASCO-GI 2023 - 2 weeks - (New C3)
MSI-H/dMMR + TMB-H
Solid Tumor
MSI-H/dMMR + TMB-H
Solid Tumor
pucotenlimab
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks (New C3)
pucotenlimab
Sensitive
:
C3
ASCO-GI 2023 - 2wk
pucotenlimab
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks
pucotenlimab
Sensitive
:
C3
ASCO-GI 2023 - 2 weeks - (New C3)
FGFR fusion
Cholangiocarcinoma
FGFR fusion
Cholangiocarcinoma
erdafitinib
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks (New C3)
erdafitinib
Sensitive
:
C3
ASCO-GI 2023 - 2wk
erdafitinib
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks
erdafitinib
Sensitive
:
C3
ASCO-GI 2023 - 2 weeks - (New C3)
FGFR mutation
Cholangiocarcinoma
FGFR mutation
Cholangiocarcinoma
erdafitinib
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks (New C3)
erdafitinib
Sensitive
:
C3
ASCO-GI 2023 - 2wk
erdafitinib
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks
erdafitinib
Sensitive
:
C3
ASCO-GI 2023 - 2 weeks - (New C3)
MUC16 elevation
Colorectal Cancer
MUC16 elevation
Colorectal Cancer
regorafenib
Resistant: C3 – Early Trials
ASCO-GI 2023 - 2 weeks (New C3)
regorafenib
Resistant
:
C3
ASCO-GI 2023 - 2wk
regorafenib
Resistant: C3 – Early Trials
ASCO-GI 2023 - 2 weeks
regorafenib
Resistant
:
C3
ASCO-GI 2023 - 2 weeks - (New C3)
MUC16 elevation
Colorectal Cancer
MUC16 elevation
Colorectal Cancer
trifluridine/tipiracil
Resistant: C3 – Early Trials
ASCO-GI 2023 - 2 weeks (New C3)
trifluridine / tipiracil
Resistant
:
C3
ASCO-GI 2023 - 2wk
trifluridine/tipiracil
Resistant: C3 – Early Trials
ASCO-GI 2023 - 2 weeks
trifluridine / tipiracil
Resistant
:
C3
ASCO-GI 2023 - 2 weeks - (New C3)
HER-2 positive
Gastric Cancer
HER-2 positive
Gastric Cancer
olaparib + durvalumab
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks (New C3)
olaparib + durvalumab
Sensitive
:
C3
ASCO-GI 2023 - 2wk
olaparib + durvalumab
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks
olaparib + durvalumab
Sensitive
:
C3
ASCO-GI 2023 - 2 weeks - (New C3)
PD-L1 expression
Gastric Cancer
PD-L1 expression
Gastric Cancer
paclitaxel + minnelide
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks (New C3)
paclitaxel + minnelide
Sensitive
:
C3
ASCO-GI 2023 - 2wk
paclitaxel + minnelide
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks
paclitaxel + minnelide
Sensitive
:
C3
ASCO-GI 2023 - 2 weeks - (New C3)
HER-2 positive
Gastric Cancer
HER-2 positive
Gastric Cancer
paclitaxel + minnelide
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks (New C3)
paclitaxel + minnelide
Sensitive
:
C3
ASCO-GI 2023 - 2wk
paclitaxel + minnelide
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks
paclitaxel + minnelide
Sensitive
:
C3
ASCO-GI 2023 - 2 weeks - (New C3)
CAPRIN-1 expression
Gastroesophageal Junction Adenocarcinoma
CAPRIN-1 expression
Gastroesophageal Junction Adenocarcinoma
ramucirumab + TRK-950
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks (New C3)
ramucirumab + TRK-950
Sensitive
:
C3
ASCO-GI 2023 - 2wk
ramucirumab + TRK-950
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks
ramucirumab + TRK-950
Sensitive
:
C3
ASCO-GI 2023 - 2 weeks - (New C3)
CAPRIN-1 expression
Gastric Cancer
CAPRIN-1 expression
Gastric Cancer
ramucirumab + TRK-950
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks (New C3)
ramucirumab + TRK-950
Sensitive
:
C3
ASCO-GI 2023 - 2wk
ramucirumab + TRK-950
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks
ramucirumab + TRK-950
Sensitive
:
C3
ASCO-GI 2023 - 2 weeks - (New C3)
CEACAM5 underexpression + MSI-H/dMMR
Colorectal Cancer
CEACAM5 underexpression + MSI-H/dMMR
Colorectal Cancer
nivolumab + ipilimumab
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks (New C3)
nivolumab + ipilimumab
Sensitive
:
C3
ASCO-GI 2023 - 2wk
nivolumab + ipilimumab
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks
nivolumab + ipilimumab
Sensitive
:
C3
ASCO-GI 2023 - 2 weeks - (New C3)
CEACAM5 underexpression + MSI-H/dMMR
Colorectal Cancer
CEACAM5 underexpression + MSI-H/dMMR
Colorectal Cancer
pembrolizumab
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks (New C3)
pembrolizumab
Sensitive
:
C3
ASCO-GI 2023 - 2wk
pembrolizumab
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks
pembrolizumab
Sensitive
:
C3
ASCO-GI 2023 - 2 weeks - (New C3)
MSI-H/dMMR + KMT2D mutation
Solid Tumor
MSI-H/dMMR + KMT2D mutation
Solid Tumor
pucotenlimab
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks (New C3)
pucotenlimab
Sensitive
:
C3
ASCO-GI 2023 - 2wk
pucotenlimab
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks
pucotenlimab
Sensitive
:
C3
ASCO-GI 2023 - 2 weeks - (New C3)
THBS2-L
Colorectal Cancer
THBS2-L
Colorectal Cancer
ramucirumab
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks (New C3)
ramucirumab
Sensitive
:
C3
ASCO-GI 2023 - 2wk
ramucirumab
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks
ramucirumab
Sensitive
:
C3
ASCO-GI 2023 - 2 weeks - (New C3)
MSI-H/dMMR + CD74 overexpression
Colorectal Cancer
MSI-H/dMMR + CD74 overexpression
Colorectal Cancer
nivolumab
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks (New C3)
nivolumab
Sensitive
:
C3
ASCO-GI 2023 - 2wk
nivolumab
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks
nivolumab
Sensitive
:
C3
ASCO-GI 2023 - 2 weeks - (New C3)
MSI-H/dMMR + HLA-DQA1 overexpression
Colorectal Cancer
MSI-H/dMMR + HLA-DQA1 overexpression
Colorectal Cancer
nivolumab
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks (New C3)
nivolumab
Sensitive
:
C3
ASCO-GI 2023 - 2wk
nivolumab
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks
nivolumab
Sensitive
:
C3
ASCO-GI 2023 - 2 weeks - (New C3)
MSI-H/dMMR + HLA-DPA1 overexpression
Colorectal Cancer
MSI-H/dMMR + HLA-DPA1 overexpression
Colorectal Cancer
nivolumab
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks (New C3)
nivolumab
Sensitive
:
C3
ASCO-GI 2023 - 2wk
nivolumab
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks
nivolumab
Sensitive
:
C3
ASCO-GI 2023 - 2 weeks - (New C3)
MSI-H/dMMR + HLA-DQB1 overexpression
Colorectal Cancer
MSI-H/dMMR + HLA-DQB1 overexpression
Colorectal Cancer
nivolumab
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks (New C3)
nivolumab
Sensitive
:
C3
ASCO-GI 2023 - 2wk
nivolumab
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks
nivolumab
Sensitive
:
C3
ASCO-GI 2023 - 2 weeks - (New C3)
MSI-H/dMMR + HLA-B overexpression
Colorectal Cancer
MSI-H/dMMR + HLA-B overexpression
Colorectal Cancer
nivolumab
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks (New C3)
nivolumab
Sensitive
:
C3
ASCO-GI 2023 - 2wk
nivolumab
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks
nivolumab
Sensitive
:
C3
ASCO-GI 2023 - 2 weeks - (New C3)
MSI-H/dMMR + HLA-DRB1 overexpression
Colorectal Cancer
MSI-H/dMMR + HLA-DRB1 overexpression
Colorectal Cancer
nivolumab
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks (New C3)
nivolumab
Sensitive
:
C3
ASCO-GI 2023 - 2wk
nivolumab
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks
nivolumab
Sensitive
:
C3
ASCO-GI 2023 - 2 weeks - (New C3)
MSI-H/dMMR + HLA-DQA1 overexpression
Colorectal Cancer
MSI-H/dMMR + HLA-DQA1 overexpression
Colorectal Cancer
pembrolizumab
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks (New C3)
pembrolizumab
Sensitive
:
C3
ASCO-GI 2023 - 2wk
pembrolizumab
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks
pembrolizumab
Sensitive
:
C3
ASCO-GI 2023 - 2 weeks - (New C3)
MSI-H/dMMR + CD74 overexpression
Colorectal Cancer
MSI-H/dMMR + CD74 overexpression
Colorectal Cancer
pembrolizumab
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks (New C3)
pembrolizumab
Sensitive
:
C3
ASCO-GI 2023 - 2wk
pembrolizumab
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks
pembrolizumab
Sensitive
:
C3
ASCO-GI 2023 - 2 weeks - (New C3)
MSI-H/dMMR + HLA-DPA1 overexpression
Colorectal Cancer
MSI-H/dMMR + HLA-DPA1 overexpression
Colorectal Cancer
pembrolizumab
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks (New C3)
pembrolizumab
Sensitive
:
C3
ASCO-GI 2023 - 2wk
pembrolizumab
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks
pembrolizumab
Sensitive
:
C3
ASCO-GI 2023 - 2 weeks - (New C3)
MSI-H/dMMR + HLA-DQB1 overexpression
Colorectal Cancer
MSI-H/dMMR + HLA-DQB1 overexpression
Colorectal Cancer
pembrolizumab
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks (New C3)
pembrolizumab
Sensitive
:
C3
ASCO-GI 2023 - 2wk
pembrolizumab
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks
pembrolizumab
Sensitive
:
C3
ASCO-GI 2023 - 2 weeks - (New C3)
MSI-H/dMMR + HLA-B overexpression
Colorectal Cancer
MSI-H/dMMR + HLA-B overexpression
Colorectal Cancer
pembrolizumab
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks (New C3)
pembrolizumab
Sensitive
:
C3
ASCO-GI 2023 - 2wk
pembrolizumab
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks
pembrolizumab
Sensitive
:
C3
ASCO-GI 2023 - 2 weeks - (New C3)
MSI-H/dMMR + HLA-DRB1 overexpression
Colorectal Cancer
MSI-H/dMMR + HLA-DRB1 overexpression
Colorectal Cancer
pembrolizumab
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks (New C3)
pembrolizumab
Sensitive
:
C3
ASCO-GI 2023 - 2wk
pembrolizumab
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks
pembrolizumab
Sensitive
:
C3
ASCO-GI 2023 - 2 weeks - (New C3)
EREG overexpression + AREG overexpression
Colorectal Cancer
EREG overexpression + AREG overexpression
Colorectal Cancer
cetuximab
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks (New C3)
cetuximab
Sensitive
:
C3
ASCO-GI 2023 - 2wk
cetuximab
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks
cetuximab
Sensitive
:
C3
ASCO-GI 2023 - 2 weeks - (New C3)
FGFR2 rearrangement
Cholangiocarcinoma
FGFR2 rearrangement
Cholangiocarcinoma
ICP-192
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks (New C3)
ICP-192
Sensitive
:
C3
ASCO-GI 2023 - 2wk
ICP-192
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks
ICP-192
Sensitive
:
C3
ASCO-GI 2023 - 2 weeks - (New C3)
MDM2 amplification
Ampulla of Vater Carcinoma
MDM2 amplification
Ampulla of Vater Carcinoma
BI 907828
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks (New C3)
BI 907828
Sensitive
:
C3
ASCO-GI 2023 - 2wk
BI 907828
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks
BI 907828
Sensitive
:
C3
ASCO-GI 2023 - 2 weeks - (New C3)
KRAS mutation
Biliary Tract Cancer
KRAS mutation
Biliary Tract Cancer
trastuzumab + pertuzumab
Resistant: C3 – Early Trials
ASCO-GI 2023 - 2 weeks (New C3)
trastuzumab + pertuzumab
Resistant
:
C3
ASCO-GI 2023 - 2wk
trastuzumab + pertuzumab
Resistant: C3 – Early Trials
ASCO-GI 2023 - 2 weeks
trastuzumab + pertuzumab
Resistant
:
C3
ASCO-GI 2023 - 2 weeks - (New C3)
ERBB3 mutation + HER-2 amplification
Biliary Tract Cancer
ERBB3 mutation + HER-2 amplification
Biliary Tract Cancer
trastuzumab + pertuzumab
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks (New C3)
trastuzumab + pertuzumab
Sensitive
:
C3
ASCO-GI 2023 - 2wk
trastuzumab + pertuzumab
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks
trastuzumab + pertuzumab
Sensitive
:
C3
ASCO-GI 2023 - 2 weeks - (New C3)
HER-2 mutation
Biliary Tract Cancer
HER-2 mutation
Biliary Tract Cancer
trastuzumab + pertuzumab
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks (New C3)
trastuzumab + pertuzumab
Sensitive
:
C3
ASCO-GI 2023 - 2wk
trastuzumab + pertuzumab
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks
trastuzumab + pertuzumab
Sensitive
:
C3
ASCO-GI 2023 - 2 weeks - (New C3)
HER-2 amplification
Biliary Tract Cancer
HER-2 amplification
Biliary Tract Cancer
trastuzumab + pertuzumab
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks (New C3)
trastuzumab + pertuzumab
Sensitive
:
C3
ASCO-GI 2023 - 2wk
trastuzumab + pertuzumab
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks
trastuzumab + pertuzumab
Sensitive
:
C3
ASCO-GI 2023 - 2 weeks - (New C3)
KRAS G12R
Pancreatic Ductal Adenocarcinoma
KRAS G12R
Pancreatic Ductal Adenocarcinoma
FOLFIRINOX
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks (New C3)
FOLFIRINOX
Sensitive
:
C3
ASCO-GI 2023 - 2wk
FOLFIRINOX
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks
FOLFIRINOX
Sensitive
:
C3
ASCO-GI 2023 - 2 weeks - (New C3)
KRAS G12R
Pancreatic Ductal Adenocarcinoma
KRAS G12R
Pancreatic Ductal Adenocarcinoma
paclitaxel + gemcitabine
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks (New C3)
paclitaxel + gemcitabine
Sensitive
:
C3
ASCO-GI 2023 - 2wk
paclitaxel + gemcitabine
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks
paclitaxel + gemcitabine
Sensitive
:
C3
ASCO-GI 2023 - 2 weeks - (New C3)
ATM mutation
Pancreatic Ductal Adenocarcinoma
ATM mutation
Pancreatic Ductal Adenocarcinoma
irinotecan
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks (New C3)
irinotecan
Sensitive
:
C3
ASCO-GI 2023 - 2wk
irinotecan
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks
irinotecan
Sensitive
:
C3
ASCO-GI 2023 - 2 weeks - (New C3)
CHEK2 mutation
Pancreatic Ductal Adenocarcinoma
CHEK2 mutation
Pancreatic Ductal Adenocarcinoma
irinotecan
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks (New C3)
irinotecan
Sensitive
:
C3
ASCO-GI 2023 - 2wk
irinotecan
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks
irinotecan
Sensitive
:
C3
ASCO-GI 2023 - 2 weeks - (New C3)
FGFR2 rearrangement
Cholangiocarcinoma
FGFR2 rearrangement
Cholangiocarcinoma
TT-00420
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks (New C3)
TT-00420
Sensitive
:
C3
ASCO-GI 2023 - 2wk
TT-00420
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks
TT-00420
Sensitive
:
C3
ASCO-GI 2023 - 2 weeks - (New C3)
MSI-H/dMMR + RAS mutation
Colorectal Cancer
MSI-H/dMMR + RAS mutation
Colorectal Cancer
Immunotherapy
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks (New C3)
Immunotherapy
Sensitive
:
C3
ASCO-GI 2023 - 2wk
Immunotherapy
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks
Immunotherapy
Sensitive
:
C3
ASCO-GI 2023 - 2 weeks - (New C3)
PD-L1 expression
Colorectal Cancer
PD-L1 expression
Colorectal Cancer
AGEN2034 + AGEN1181
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks (New C3)
AGEN2034 + AGEN1181
Sensitive
:
C3
ASCO-GI 2023 - 2wk
AGEN2034 + AGEN1181
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks
AGEN2034 + AGEN1181
Sensitive
:
C3
ASCO-GI 2023 - 2 weeks - (New C3)
NRAS mutation
Colorectal Cancer
NRAS mutation
Colorectal Cancer
AGEN2034 + AGEN1181
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks (New C3)
AGEN2034 + AGEN1181
Sensitive
:
C3
ASCO-GI 2023 - 2wk
AGEN2034 + AGEN1181
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks
AGEN2034 + AGEN1181
Sensitive
:
C3
ASCO-GI 2023 - 2 weeks - (New C3)
KRAS mutation
Colorectal Cancer
KRAS mutation
Colorectal Cancer
AGEN2034 + AGEN1181
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks (New C3)
AGEN2034 + AGEN1181
Sensitive
:
C3
ASCO-GI 2023 - 2wk
AGEN2034 + AGEN1181
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks
AGEN2034 + AGEN1181
Sensitive
:
C3
ASCO-GI 2023 - 2 weeks - (New C3)
CHEK2 mutation
Prostate Cancer
CHEK2 mutation
Prostate Cancer
pembrolizumab
Sensitive: C4 – Case Studies
BMJ Case Rep - 2 weeks (New C4)
pembrolizumab
Sensitive
:
C4
BMJ Case Rep - 2wk
pembrolizumab
Sensitive: C4 – Case Studies
BMJ Case Rep - 2 weeks
pembrolizumab
Sensitive
:
C4
BMJ Case Rep - 2 weeks - (New C4)
BAP1 mutation + IDH2 R172W + CDKN2A deletion + CDKN2B deletion
Cholangiocarcinoma
BAP1 mutation + IDH2 R172W + CDKN2A deletion + CDKN2B deletion
Cholangiocarcinoma
palbociclib
Sensitive: C4 – Case Studies
Onco Targets Ther - 2 weeks (New C4)
palbociclib
Sensitive
:
C4
Onco Targets Ther - 2wk
palbociclib
Sensitive: C4 – Case Studies
Onco Targets Ther - 2 weeks
palbociclib
Sensitive
:
C4
Onco Targets Ther - 2 weeks - (New C4)
CAPZA2-MET fusion + MET amplification
Cholangiocarcinoma
CAPZA2-MET fusion + MET amplification
Cholangiocarcinoma
capmatinib
Sensitive: C4 – Case Studies
The Oncologist - 2 weeks (New C4)
capmatinib
Sensitive
:
C4
The Oncologist - 2wk
capmatinib
Sensitive: C4 – Case Studies
The Oncologist - 2 weeks
capmatinib
Sensitive
:
C4
The Oncologist - 2 weeks - (New C4)
EGFR exon 19 deletion + EGFR C797S
Lung Adenocarcinoma
EGFR exon 19 deletion + EGFR C797S
Lung Adenocarcinoma
osimertinib + anlotinib
Sensitive: C4 – Case Studies
Pharmacol Res - 2 weeks (New C4)
osimertinib + anlotinib
Sensitive
:
C4
Pharmacol Res - 2wk
osimertinib + anlotinib
Sensitive: C4 – Case Studies
Pharmacol Res - 2 weeks
osimertinib + anlotinib
Sensitive
:
C4
Pharmacol Res - 2 weeks - (New C4)
PIK3CA mutation
Colorectal Cancer
PIK3CA mutation
Colorectal Cancer
alpelisib + ribociclib
Sensitive: D – Preclinical
ASCO-GI 2023 - 2 weeks (New D)
alpelisib + ribociclib
Sensitive
:
D
ASCO-GI 2023 - 2wk
alpelisib + ribociclib
Sensitive: D – Preclinical
ASCO-GI 2023 - 2 weeks
alpelisib + ribociclib
Sensitive
:
D
ASCO-GI 2023 - 2 weeks - (New D)
KRAS mutation
Colorectal Cancer
KRAS mutation
Colorectal Cancer
alpelisib + ribociclib
Sensitive: D – Preclinical
ASCO-GI 2023 - 2 weeks (New D)
alpelisib + ribociclib
Sensitive
:
D
ASCO-GI 2023 - 2wk
alpelisib + ribociclib
Sensitive: D – Preclinical
ASCO-GI 2023 - 2 weeks
alpelisib + ribociclib
Sensitive
:
D
ASCO-GI 2023 - 2 weeks - (New D)
EGFR L860R
Lung Adenocarcinoma
EGFR L860R
Lung Adenocarcinoma
osimertinib
Sensitive: D – Preclinical
Cancer Lett - 2 weeks (New D)
osimertinib
Sensitive
:
D
Cancer Lett - 2wk
osimertinib
Sensitive: D – Preclinical
Cancer Lett - 2 weeks
osimertinib
Sensitive
:
D
Cancer Lett - 2 weeks - (New D)
MSI-H/dMMR + HLA-DPB1 overexpression
Colorectal Cancer
MSI-H/dMMR + HLA-DPB1 overexpression
Colorectal Cancer
nivolumab
Sensitive: D – Preclinical
ASCO-GI 2023 - 2 weeks (New D)
nivolumab
Sensitive
:
D
ASCO-GI 2023 - 2wk
nivolumab
Sensitive: D – Preclinical
ASCO-GI 2023 - 2 weeks
nivolumab
Sensitive
:
D
ASCO-GI 2023 - 2 weeks - (New D)
MSI-H/dMMR + HLA-DPB1 overexpression
Colorectal Cancer
MSI-H/dMMR + HLA-DPB1 overexpression
Colorectal Cancer
pembrolizumab
Sensitive: D – Preclinical
ASCO-GI 2023 - 2 weeks (New D)
pembrolizumab
Sensitive
:
D
ASCO-GI 2023 - 2wk
pembrolizumab
Sensitive: D – Preclinical
ASCO-GI 2023 - 2 weeks
pembrolizumab
Sensitive
:
D
ASCO-GI 2023 - 2 weeks - (New D)
PIK3CA mutation + KRAS mutation
Colorectal Cancer
PIK3CA mutation + KRAS mutation
Colorectal Cancer
alpelisib + ribociclib
Sensitive: D – Preclinical
ASCO-GI 2023 - 2 weeks (New D)
alpelisib + ribociclib
Sensitive
:
D
ASCO-GI 2023 - 2wk
alpelisib + ribociclib
Sensitive: D – Preclinical
ASCO-GI 2023 - 2 weeks
alpelisib + ribociclib
Sensitive
:
D
ASCO-GI 2023 - 2 weeks - (New D)
PIK3CA wild-type + KRAS wild-type
Colorectal Cancer
PIK3CA wild-type + KRAS wild-type
Colorectal Cancer
alpelisib + ribociclib
Sensitive: D – Preclinical
ASCO-GI 2023 - 2 weeks (New D)
alpelisib + ribociclib
Sensitive
:
D
ASCO-GI 2023 - 2wk
alpelisib + ribociclib
Sensitive: D – Preclinical
ASCO-GI 2023 - 2 weeks
alpelisib + ribociclib
Sensitive
:
D
ASCO-GI 2023 - 2 weeks - (New D)
No biomarker
Hodgkin Lymphoma
No biomarker
Hodgkin Lymphoma
Bv-AVE-PC
Sensitive: A2 - Guideline
NCCN - 3 weeks (New A2)
Bv-AVE-PC
Sensitive
:
A2
NCCN - 3wk
Bv-AVE-PC
Sensitive: A2 - Guideline
NCCN - 3 weeks
Bv-AVE-PC
Sensitive
:
A2
NCCN - 3 weeks - (New A2)
No biomarker
Hodgkin Lymphoma
No biomarker
Hodgkin Lymphoma
AEPA-CAPDAC
Sensitive: A2 - Guideline
NCCN - 3 weeks (New A2)
AEPA-CAPDAC
Sensitive
:
A2
NCCN - 3wk
AEPA-CAPDAC
Sensitive: A2 - Guideline
NCCN - 3 weeks
AEPA-CAPDAC
Sensitive
:
A2
NCCN - 3 weeks - (New A2)
No biomarker
Hodgkin Lymphoma
No biomarker
Hodgkin Lymphoma
CVbP
Sensitive: A2 - Guideline
NCCN - 3 weeks (New A2)
CVbP
Sensitive
:
A2
NCCN - 3wk
CVbP
Sensitive: A2 - Guideline
NCCN - 3 weeks
CVbP
Sensitive
:
A2
NCCN - 3 weeks - (New A2)
No biomarker
Hodgkin Lymphoma
No biomarker
Hodgkin Lymphoma
CHOP
Sensitive: A2 - Guideline
NCCN - 3 weeks (New A2)
CHOP
Sensitive
:
A2
NCCN - 3wk
CHOP
Sensitive: A2 - Guideline
NCCN - 3 weeks
CHOP
Sensitive
:
A2
NCCN - 3 weeks - (New A2)
No biomarker
Hodgkin Lymphoma
No biomarker
Hodgkin Lymphoma
OEPA
Sensitive: A2 - Guideline
NCCN - 3 weeks (New A2)
OEPA
Sensitive
:
A2
NCCN - 3wk
OEPA
Sensitive: A2 - Guideline
NCCN - 3 weeks
OEPA
Sensitive
:
A2
NCCN - 3 weeks - (New A2)
No biomarker
Hodgkin Lymphoma
No biomarker
Hodgkin Lymphoma
ABVE-PC
Sensitive: A2 - Guideline
NCCN - 3 weeks (New A2)
ABVE-PC
Sensitive
:
A2
NCCN - 3wk
ABVE-PC
Sensitive: A2 - Guideline
NCCN - 3 weeks
ABVE-PC
Sensitive
:
A2
NCCN - 3 weeks - (New A2)
ER positive
HER2 Negative Breast Cancer
ER positive
HER2 Negative Breast Cancer
CFI-402257
Sensitive: B - Late Trials
Treadwell Therap Press Release - 3 weeks (New B)
CFI-402257
Sensitive
:
B
Treadwell Therap Press Release - 3wk
CFI-402257
Sensitive: B - Late Trials
Treadwell Therap Press Release - 3 weeks
CFI-402257
Sensitive
:
B
Treadwell Therap Press Release - 3 weeks - (New B)
No biomarker
Diffuse Large B Cell Lymphoma
No biomarker
Diffuse Large B Cell Lymphoma
RG6026
Sensitive: B - Late Trials
Roche Press Release - 3 weeks (New B)
RG6026
Sensitive
:
B
Roche Press Release - 3wk
RG6026
Sensitive: B - Late Trials
Roche Press Release - 3 weeks
RG6026
Sensitive
:
B
Roche Press Release - 3 weeks - (New B)
MYCL expression
Non Small Cell Lung Cancer
MYCL expression
Non Small Cell Lung Cancer
MRT-2359
Sensitive: B - Late Trials
Monte Rosa Therap Press Release - 3 weeks (New B)
MRT-2359
Sensitive
:
B
Monte Rosa Therap Press Release - 3wk
MRT-2359
Sensitive: B - Late Trials
Monte Rosa Therap Press Release - 3 weeks
MRT-2359
Sensitive
:
B
Monte Rosa Therap Press Release - 3 weeks - (New B)
MYCN expression
Non Small Cell Lung Cancer
MYCN expression
Non Small Cell Lung Cancer
MRT-2359
Sensitive: B - Late Trials
Monte Rosa Therap Press Release - 3 weeks (New B)
MRT-2359
Sensitive
:
B
Monte Rosa Therap Press Release - 3wk
MRT-2359
Sensitive: B - Late Trials
Monte Rosa Therap Press Release - 3 weeks
MRT-2359
Sensitive
:
B
Monte Rosa Therap Press Release - 3 weeks - (New B)
HER-2 positive
HER2 Positive Breast Cancer
HER-2 positive
HER2 Positive Breast Cancer
trastuzumab + pertuzumab
Sensitive: A1 - Approval
Breast Cancer - 3 weeks (New C3)
trastuzumab + pertuzumab
Sensitive
:
A1
Breast Cancer - 3wk
trastuzumab + pertuzumab
Sensitive: A1 - Approval
Breast Cancer - 3 weeks
trastuzumab + pertuzumab
Sensitive
:
A1
Breast Cancer - 3 weeks - (New C3)
EGFR exon 20 insertion
Non Small Cell Lung Cancer
EGFR exon 20 insertion
Non Small Cell Lung Cancer
mobocertinib
Sensitive: A1 - Approval
Takeda Press Release - 3 weeks (New A1)
mobocertinib
Sensitive
:
A1
Takeda Press Release - 3wk
mobocertinib
Sensitive: A1 - Approval
Takeda Press Release - 3 weeks
mobocertinib
Sensitive
:
A1
Takeda Press Release - 3 weeks - (New A1)
HER-2 positive
HER2 Positive Breast Cancer
HER-2 positive
HER2 Positive Breast Cancer
trastuzumab
Sensitive: A1 - Approval
Ther Adv Med Oncol - 3 weeks (New C3)
trastuzumab
Sensitive
:
A1
Ther Adv Med Oncol - 3wk
trastuzumab
Sensitive: A1 - Approval
Ther Adv Med Oncol - 3 weeks
trastuzumab
Sensitive
:
A1
Ther Adv Med Oncol - 3 weeks - (New C3)
MSI-H/dMMR
Solid Tumor
MSI-H/dMMR
Solid Tumor
pembrolizumab
Sensitive: A1 - Approval
J Clin Oncol - 3 weeks (New C3)
pembrolizumab
Sensitive
:
A1
J Clin Oncol - 3wk
pembrolizumab
Sensitive: A1 - Approval
J Clin Oncol - 3 weeks
pembrolizumab
Sensitive
:
A1
J Clin Oncol - 3 weeks - (New C3)
HRD
Ovarian Cancer
HRD
Ovarian Cancer
bevacizumab + olaparib
Sensitive: A1 - Approval
Eur J Cancer - 3 weeks (New B)
bevacizumab + olaparib
Sensitive
:
A1
Eur J Cancer - 3wk
bevacizumab + olaparib
Sensitive: A1 - Approval
Eur J Cancer - 3 weeks
bevacizumab + olaparib
Sensitive
:
A1
Eur J Cancer - 3 weeks - (New B)
PIK3CA mutation + HR positive
HER2 Negative Breast Cancer
PIK3CA mutation + HR positive
HER2 Negative Breast Cancer
alpelisib
Sensitive: A1 - Approval
Oncogene - 3 weeks (New C3)
alpelisib
Sensitive
:
A1
Oncogene - 3wk
alpelisib
Sensitive: A1 - Approval
Oncogene - 3 weeks
alpelisib
Sensitive
:
A1
Oncogene - 3 weeks - (New C3)
BRCA1 mutation
Ovarian Cancer
BRCA1 mutation
Ovarian Cancer
bevacizumab + olaparib
Sensitive: A1 - Approval
Eur J Cancer - 3 weeks (New B)
bevacizumab + olaparib
Sensitive
:
A1
Eur J Cancer - 3wk
bevacizumab + olaparib
Sensitive: A1 - Approval
Eur J Cancer - 3 weeks
bevacizumab + olaparib
Sensitive
:
A1
Eur J Cancer - 3 weeks - (New B)
BRCA2 mutation
Ovarian Cancer
BRCA2 mutation
Ovarian Cancer
bevacizumab + olaparib
Sensitive: A1 - Approval
Eur J Cancer - 3 weeks (New B)
bevacizumab + olaparib
Sensitive
:
A1
Eur J Cancer - 3wk
bevacizumab + olaparib
Sensitive: A1 - Approval
Eur J Cancer - 3 weeks
bevacizumab + olaparib
Sensitive
:
A1
Eur J Cancer - 3 weeks - (New B)
PD-L1 underexpression
Melanoma
PD-L1 underexpression
Melanoma
nivolumab/relatlimab
Sensitive: A1 - Approval
N Engl J Med - 3 weeks (New B)
nivolumab / relatlimab
Sensitive
:
A1
N Engl J Med - 3wk
nivolumab/relatlimab
Sensitive: A1 - Approval
N Engl J Med - 3 weeks
nivolumab / relatlimab
Sensitive
:
A1
N Engl J Med - 3 weeks - (New B)
HER-2 positive
HER2 Positive Breast Cancer
HER-2 positive
HER2 Positive Breast Cancer
lapatinib
Sensitive: A2 - Guideline
Eur J Cancer - 3 weeks (New B)
lapatinib
Sensitive
:
A2
Eur J Cancer - 3wk
lapatinib
Sensitive: A2 - Guideline
Eur J Cancer - 3 weeks
lapatinib
Sensitive
:
A2
Eur J Cancer - 3 weeks - (New B)
HRAS mutation
Squamous Cell Carcinoma of Head and Neck
HRAS mutation
Squamous Cell Carcinoma of Head and Neck
tipifarnib
Sensitive: B - Late Trials
JCO Precis Oncol - 3 weeks (New C3)
tipifarnib
Sensitive
:
B
JCO Precis Oncol - 3wk
tipifarnib
Sensitive: B - Late Trials
JCO Precis Oncol - 3 weeks
tipifarnib
Sensitive
:
B
JCO Precis Oncol - 3 weeks - (New C3)
BRAF V600E
Thyroid Gland Papillary Carcinoma
BRAF V600E
Thyroid Gland Papillary Carcinoma
vemurafenib
Sensitive: C1 - Off-label
J Transl Med - 3 weeks (New D)
vemurafenib
Sensitive
:
C1
J Transl Med - 3wk
vemurafenib
Sensitive: C1 - Off-label
J Transl Med - 3 weeks
vemurafenib
Sensitive
:
C1
J Transl Med - 3 weeks - (New D)
BRAF V600E
Thyroid Gland Papillary Carcinoma
BRAF V600E
Thyroid Gland Papillary Carcinoma
dabrafenib
Sensitive: C1 - Off-label
J Transl Med - 3 weeks (New D)
dabrafenib
Sensitive
:
C1
J Transl Med - 3wk
dabrafenib
Sensitive: C1 - Off-label
J Transl Med - 3 weeks
dabrafenib
Sensitive
:
C1
J Transl Med - 3 weeks - (New D)
PBRM1 mutation
Non Small Cell Lung Cancer
PBRM1 mutation
Non Small Cell Lung Cancer
Immunotherapy
Resistant: C3 – Early Trials
Front Genet - 3 weeks (New C3)
Immunotherapy
Resistant
:
C3
Front Genet - 3wk
Immunotherapy
Resistant: C3 – Early Trials
Front Genet - 3 weeks
Immunotherapy
Resistant
:
C3
Front Genet - 3 weeks - (New C3)
EGFR mutation
Non Small Cell Lung Cancer
EGFR mutation
Non Small Cell Lung Cancer
BPI-7711
Sensitive: C3 – Early Trials
BMC Med - 3 weeks (New C3)
BPI-7711
Sensitive
:
C3
BMC Med - 3wk
BPI-7711
Sensitive: C3 – Early Trials
BMC Med - 3 weeks
BPI-7711
Sensitive
:
C3
BMC Med - 3 weeks - (New C3)
EGFR mutation
Non Small Cell Lung Cancer
EGFR mutation
Non Small Cell Lung Cancer
gefitinib + AB-329
Sensitive: C3 – Early Trials
Cancer Med - 3 weeks (New C3)
gefitinib + AB-329
Sensitive
:
C3
Cancer Med - 3wk
gefitinib + AB-329
Sensitive: C3 – Early Trials
Cancer Med - 3 weeks
gefitinib + AB-329
Sensitive
:
C3
Cancer Med - 3 weeks - (New C3)
EGFR mutation
Non Small Cell Lung Cancer
EGFR mutation
Non Small Cell Lung Cancer
osimertinib + MEDI9447
Sensitive: C3 – Early Trials
J Thorac Oncol - 3 weeks (New C3)
osimertinib + MEDI9447
Sensitive
:
C3
J Thorac Oncol - 3wk
osimertinib + MEDI9447
Sensitive: C3 – Early Trials
J Thorac Oncol - 3 weeks
osimertinib + MEDI9447
Sensitive
:
C3
J Thorac Oncol - 3 weeks - (New C3)
BRCA wild-type
Ovarian Cancer
BRCA wild-type
Ovarian Cancer
carboplatin + paclitaxel
Sensitive: C3 – Early Trials
Int J Gynecol Cancer - 3 weeks (New C3)
carboplatin + paclitaxel
Sensitive
:
C3
Int J Gynecol Cancer - 3wk
carboplatin + paclitaxel
Sensitive: C3 – Early Trials
Int J Gynecol Cancer - 3 weeks
carboplatin + paclitaxel
Sensitive
:
C3
Int J Gynecol Cancer - 3 weeks - (New C3)
BRCA1 mutation
Ovarian Cancer
BRCA1 mutation
Ovarian Cancer
carboplatin + pegylated liposomal doxorubicin
Sensitive: C3 – Early Trials
Int J Gynecol Cancer - 3 weeks (New C3)
carboplatin + pegylated liposomal doxorubicin
Sensitive
:
C3
Int J Gynecol Cancer - 3wk
carboplatin + pegylated liposomal doxorubicin
Sensitive: C3 – Early Trials
Int J Gynecol Cancer - 3 weeks
carboplatin + pegylated liposomal doxorubicin
Sensitive
:
C3
Int J Gynecol Cancer - 3 weeks - (New C3)
BRCA2 mutation
Ovarian Cancer
BRCA2 mutation
Ovarian Cancer
carboplatin + pegylated liposomal doxorubicin
Sensitive: C3 – Early Trials
Int J Gynecol Cancer - 3 weeks (New C3)
carboplatin + pegylated liposomal doxorubicin
Sensitive
:
C3
Int J Gynecol Cancer - 3wk
carboplatin + pegylated liposomal doxorubicin
Sensitive: C3 – Early Trials
Int J Gynecol Cancer - 3 weeks
carboplatin + pegylated liposomal doxorubicin
Sensitive
:
C3
Int J Gynecol Cancer - 3 weeks - (New C3)
KRAS mutation + TP53 mutation + PD-L1 expression + PD-1 expression
Non Small Cell Lung Cancer
KRAS mutation + TP53 mutation + PD-L1 expression + PD-1 expression
Non Small Cell Lung Cancer
anlotinib + camrelizumab
Sensitive: C4 – Case Studies
Front Pharmacol - 3 weeks (New C4)
anlotinib + camrelizumab
Sensitive
:
C4
Front Pharmacol - 3wk
anlotinib + camrelizumab
Sensitive: C4 – Case Studies
Front Pharmacol - 3 weeks
anlotinib + camrelizumab
Sensitive
:
C4
Front Pharmacol - 3 weeks - (New C4)
No biomarker
Marginal Zone Lymphoma
No biomarker
Marginal Zone Lymphoma
zanubrutinib
Sensitive: A1 - Approval
zanubrutinib
Sensitive
:
A1
zanubrutinib
Sensitive: A1 - Approval
zanubrutinib
Sensitive
:
A1
No biomarker
Multiple Myeloma
No biomarker
Multiple Myeloma
pomalidomide + elotuzumab
Sensitive: A1 - Approval
pomalidomide + elotuzumab
Sensitive
:
A1
pomalidomide + elotuzumab
Sensitive: A1 - Approval
pomalidomide + elotuzumab
Sensitive
:
A1
No biomarker
Diffuse Large B Cell Lymphoma
No biomarker
Diffuse Large B Cell Lymphoma
lisocabtagene maraleucel
Sensitive: A1 - Approval
lisocabtagene maraleucel
Sensitive
:
A1
lisocabtagene maraleucel
Sensitive: A1 - Approval
lisocabtagene maraleucel
Sensitive
:
A1
CD20 positive
Chronic Lymphocytic Leukemia
CD20 positive
Chronic Lymphocytic Leukemia
rituximab-abbs
Sensitive: A1 - Approval
rituximab-abbs
Sensitive
:
A1
rituximab-abbs
Sensitive: A1 - Approval
rituximab-abbs
Sensitive
:
A1
PD-L1 expression
Non Small Cell Lung Cancer
PD-L1 expression
Non Small Cell Lung Cancer
atezolizumab
Sensitive: A1 - Approval
atezolizumab
Sensitive
:
A1
atezolizumab
Sensitive: A1 - Approval
atezolizumab
Sensitive
:
A1
EGFR exon 19 deletion
Non Small Cell Lung Cancer
EGFR exon 19 deletion
Non Small Cell Lung Cancer
afatinib
Sensitive: A1 - Approval
afatinib
Sensitive
:
A1
afatinib
Sensitive: A1 - Approval
afatinib
Sensitive
:
A1
No biomarker
Non Small Cell Lung Cancer
No biomarker
Non Small Cell Lung Cancer
ramucirumab
Sensitive: A1 - Approval
ramucirumab
Sensitive
:
A1
ramucirumab
Sensitive: A1 - Approval
ramucirumab
Sensitive
:
A1
MSI-H/dMMR
Small Intestinal Carcinoma
MSI-H/dMMR
Small Intestinal Carcinoma
pembrolizumab
Sensitive: A1 - Approval
pembrolizumab
Sensitive
:
A1
pembrolizumab
Sensitive: A1 - Approval
pembrolizumab
Sensitive
:
A1
ALK positive
Non Small Cell Lung Cancer
ALK positive
Non Small Cell Lung Cancer
lorlatinib
Sensitive: A1 - Approval
lorlatinib
Sensitive
:
A1
lorlatinib
Sensitive: A1 - Approval
lorlatinib
Sensitive
:
A1
EGFR exon 19 deletion
Non Small Cell Lung Cancer
EGFR exon 19 deletion
Non Small Cell Lung Cancer
gefitinib
Sensitive: A1 - Approval
gefitinib
Sensitive
:
A1
gefitinib
Sensitive: A1 - Approval
gefitinib
Sensitive
:
A1
PD-L1 expression
Triple Negative Breast Cancer
PD-L1 expression
Triple Negative Breast Cancer
atezolizumab
Sensitive: A1 - Approval
atezolizumab
Sensitive
:
A1
atezolizumab
Sensitive: A1 - Approval
atezolizumab
Sensitive
:
A1
EGFR L858R
Non Small Cell Lung Cancer
EGFR L858R
Non Small Cell Lung Cancer
afatinib
Sensitive: A1 - Approval
afatinib
Sensitive
:
A1
afatinib
Sensitive: A1 - Approval
afatinib
Sensitive
:
A1
No biomarker
Non Small Cell Lung Cancer
No biomarker
Non Small Cell Lung Cancer
durvalumab
Sensitive: A1 - Approval
durvalumab
Sensitive
:
A1
durvalumab
Sensitive: A1 - Approval
durvalumab
Sensitive
:
A1
HER-2 positive
HER2 Positive Breast Cancer
HER-2 positive
HER2 Positive Breast Cancer
trastuzumab + tucatinib
Sensitive: A1 - Approval
trastuzumab + tucatinib
Sensitive
:
A1
trastuzumab + tucatinib
Sensitive: A1 - Approval
trastuzumab + tucatinib
Sensitive
:
A1
KIT positive
Gastrointestinal Stromal Tumor
KIT positive
Gastrointestinal Stromal Tumor
imatinib
Sensitive: A1 - Approval
imatinib
Sensitive
:
A1
imatinib
Sensitive: A1 - Approval
imatinib
Sensitive
:
A1
HER-2 positive
HER2 Positive Breast Cancer
HER-2 positive
HER2 Positive Breast Cancer
margetuximab
Sensitive: A1 - Approval
margetuximab
Sensitive
:
A1
margetuximab
Sensitive: A1 - Approval
margetuximab
Sensitive
:
A1
No biomarker
Renal Cell Carcinoma
No biomarker
Renal Cell Carcinoma
nivolumab + cabozantinib tablet
Sensitive: A1 - Approval
nivolumab + cabozantinib tablet
Sensitive
:
A1
nivolumab + cabozantinib tablet
Sensitive: A1 - Approval
nivolumab + cabozantinib tablet
Sensitive
:
A1
No biomarker
Malignant Pleural Mesothelioma
No biomarker
Malignant Pleural Mesothelioma
nivolumab + ipilimumab
Sensitive: A1 - Approval
nivolumab + ipilimumab
Sensitive
:
A1
nivolumab + ipilimumab
Sensitive: A1 - Approval
nivolumab + ipilimumab
Sensitive
:
A1
PD-L1 expression
Non Small Cell Lung Cancer
PD-L1 expression
Non Small Cell Lung Cancer
pembrolizumab
Sensitive: A1 - Approval
pembrolizumab
Sensitive
:
A1
pembrolizumab
Sensitive: A1 - Approval
pembrolizumab
Sensitive
:
A1
ALK fusion
Non Small Cell Lung Cancer
ALK fusion
Non Small Cell Lung Cancer
brigatinib
Sensitive: A1 - Approval
brigatinib
Sensitive
:
A1
brigatinib
Sensitive: A1 - Approval
brigatinib
Sensitive
:
A1
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
trastuzumab
Sensitive: A1 - Approval
trastuzumab
Sensitive
:
A1
trastuzumab
Sensitive: A1 - Approval
trastuzumab
Sensitive
:
A1
No biomarker
Follicular Lymphoma
No biomarker
Follicular Lymphoma
axicabtagene ciloleucel
Sensitive: A1 - Approval
axicabtagene ciloleucel
Sensitive
:
A1
axicabtagene ciloleucel
Sensitive: A1 - Approval
axicabtagene ciloleucel
Sensitive
:
A1
No biomarker
Diffuse Large B Cell Lymphoma
No biomarker
Diffuse Large B Cell Lymphoma
axicabtagene ciloleucel
Sensitive: A1 - Approval
axicabtagene ciloleucel
Sensitive
:
A1
axicabtagene ciloleucel
Sensitive: A1 - Approval
axicabtagene ciloleucel
Sensitive
:
A1
No biomarker
Mediastinal B Cell Lymphoma
No biomarker
Mediastinal B Cell Lymphoma
axicabtagene ciloleucel
Sensitive: A1 - Approval
axicabtagene ciloleucel
Sensitive
:
A1
axicabtagene ciloleucel
Sensitive: A1 - Approval
axicabtagene ciloleucel
Sensitive
:
A1
PDGFRA D842V
Gastrointestinal Stromal Tumor
PDGFRA D842V
Gastrointestinal Stromal Tumor
avapritinib
Sensitive: A1 - Approval
avapritinib
Sensitive
:
A1
avapritinib
Sensitive: A1 - Approval
avapritinib
Sensitive
:
A1
No biomarker
Gastroesophageal Junction Adenocarcinoma
No biomarker
Gastroesophageal Junction Adenocarcinoma
nivolumab
Sensitive: A1 - Approval
nivolumab
Sensitive
:
A1
nivolumab
Sensitive: A1 - Approval
nivolumab
Sensitive
:
A1
No biomarker
Esophageal Cancer
No biomarker
Esophageal Cancer
nivolumab
Sensitive: A1 - Approval
nivolumab
Sensitive
:
A1
nivolumab
Sensitive: A1 - Approval
nivolumab
Sensitive
:
A1
No biomarker
Esophageal Squamous Cell Carcinoma
No biomarker
Esophageal Squamous Cell Carcinoma
nivolumab
Sensitive: A1 - Approval
nivolumab
Sensitive
:
A1
nivolumab
Sensitive: A1 - Approval
nivolumab
Sensitive
:
A1
No biomarker
Fallopian Tube Cancer
No biomarker
Fallopian Tube Cancer
niraparib
Sensitive: A1 - Approval
niraparib
Sensitive
:
A1
niraparib
Sensitive: A1 - Approval
niraparib
Sensitive
:
A1
No biomarker
Ovarian Cancer
No biomarker
Ovarian Cancer
niraparib
Sensitive: A1 - Approval
niraparib
Sensitive
:
A1
niraparib
Sensitive: A1 - Approval
niraparib
Sensitive
:
A1
No biomarker
Peritoneal Cancer
No biomarker
Peritoneal Cancer
niraparib
Sensitive: A1 - Approval
niraparib
Sensitive
:
A1
niraparib
Sensitive: A1 - Approval
niraparib
Sensitive
:
A1
No biomarker
Mantle Cell Lymphoma
No biomarker
Mantle Cell Lymphoma
brexucabtagene autoleucel
Sensitive: A1 - Approval
brexucabtagene autoleucel
Sensitive
:
A1
brexucabtagene autoleucel
Sensitive: A1 - Approval
brexucabtagene autoleucel
Sensitive
:
A1
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login